The timing and impact of psychiatric, cognitive and motor abnormalities in Huntington's disease

Branduff McAllister, BSc, PhD[1], James F. Gusella, PhD[2], G. Bernhard Landwehrmeyer, MD PhD[3], Jong-Min Lee, PhD[2], Marcy E. MacDonald, PhD[2], Michael Orth, MD PhD[4], Anne E. Rosser, MB BChir, FRCP, PhD[5,6], Nigel M. Williams, BSc, PhD[1], Peter Holmans, BA, PhD[1], Lesley Jones, BSc, PhD[1]* & Thomas H. Massey, MA, BM BCh, DPhil[1]* on behalf of the REGISTRY Investigators of the European Huntington's disease network[7]

1 Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, United Kingdom
2 Molecular Neurogenetic Unit, Center for Genomic Medicine, Massachusetts General Hospital and Department of Genetics, Harvard Medical School, Boston MA 02114 USA
3 University of Ulm, Department of Neurology, Ulm, Germany
4 Swiss Huntington's disease Centre, Siloah, Bern, Switzerland
5 Brain Repair Group, Schools of Medicine and Biosciences, Cardiff University, Cardiff, United Kingdom
6 Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, United Kingdom
7 See Appendix 2

* Corresponding authors
Lesley Jones, Hadyn Ellis Building, Cardiff University, Cardiff CF24 4HQ, United Kingdom. Phone: 00442920688469. Email: JonesL1@cardiff.ac.uk
Thomas Massey, Hadyn Ellis Building, Cardiff University, Cardiff CF24 4HQ, United Kingdom. Phone: 00442920688353. Email: MasseyT1@cardiff.ac.uk

Word count: 4500

Key words: Huntington, onset, symptom, psychiatric, cognitive

Financial disclosures related to this manuscript: none

Funding sources: BMc was supported by a PhD studentship from Cardiff University School of Medicine. TM was supported by a Welsh Clinical Academic Track Fellowship, an MRC Clinical Training Fellowship (MR/P001629/1) and a Patrick Berthoud Charitable Trust Fellowship through the Association of British Neurologists. LJ, NW and PH were supported by an MRC Centre grant (MR/L010305/1).

Abstract

Objective

To assess the prevalence, timing and functional impact of psychiatric, cognitive and motor abnormalities in Huntington's disease (HD) gene carriers, we analysed retrospective clinical data from individuals with manifest HD.

Methods

Clinical features of HD patients were analysed for 6316 individuals in the European REGISTRY study from 161 sites across 17 countries. Data came from clinical history and the patient-completed Clinical Characteristics Questionnaire that assessed eight symptoms: motor, cognitive, apathy, depression, perseverative/obsessive behavior, irritability, violent/aggressive behavior, and psychosis. Multiple logistic regression was used to analyse relationships between symptoms and functional outcomes.

Results

The initial manifestation of HD is increasingly likely to be motor, and less likely to be psychiatric, as age at presentation increases, and is independent of pathogenic CAG repeat length. The Clinical Characteristics Questionnaire captures data on non-motor symptom prevalence that correlate specifically with validated clinical measures. Psychiatric and cognitive symptoms are common in HD gene carriers, with earlier onsets associated with longer CAG repeats. 42.4% of HD patients reported at least one psychiatric or cognitive symptom before motor symptoms, with depression most common. Each non-motor symptom was associated with significantly reduced total functional capacity scores.

Conclusions

Psychiatric and cognitive symptoms are common and functionally debilitating in HD gene carriers. They require recognition and targeting with clinical outcome measures and treatments. However, as it is impossible to distinguish confidently between non-motor symptoms arising from HD and primary psychiatric disorders, particularly in younger pre-manifest patients, non-motor symptoms should not be used to make a clinical diagnosis of HD.

Introduction

Huntington's disease (HD) is a central neurodegenerative disorder caused by an expanded CAG repeat (>35 CAGs) in the *Huntingtin* gene[1]. Longer repeats are associated with earlier disease onset[2,3]. Neuronal loss in the brain causes progressive motor abnormalities, cognitive decline and ultimately death. The movement disorder usually includes chorea, but may also involve dystonia, ataxia, oculomotor problems and parkinsonism, some of which are initially only identifiable through targeted HD examination. Debilitating behavioral and psychiatric symptoms are common in HD gene carriers, and require treatment, although they cannot be used in clinical practice to define HD onset because it is impossible to distinguish psychiatric manifestations of HD from coincident diagnoses[4,5]. Prospective studies of HD gene carriers many years from predicted clinical onset have shown only subtle motor, cognitive and psychiatric deficits when compared with age and sex-matched controls[6–8]. This implies there is a window for therapeutic intervention to preserve normal brain functions. Understanding in detail the timing and impact of different symptoms in HD gene carriers will help improve targeted therapies.

The HD Clinical Characteristics Questionnaire (HD-CCQ)[9] gathers retrospective data from individuals with HD about the prevalence and timing of eight motor, cognitive and psychiatric symptoms[10]. Here we validate HD-CCQ data for non-motor symptoms by showing strong and specific associations with established scores of depression, irritability and cognition. We use HD-CCQ data to show the high prevalence of psychiatric and cognitive symptoms in HD gene carriers, often in advance of motor symptoms, and their negative impact on the lives of patients.

Methods

Standard protocol approvals, registrations and patient consents

Participants were in the multicentre, multinational, observational REGISTRY study of European HD (http://www.ehdn.org/wp-content/uploads/2018/06/registry-protocol-3.0.pdf; NCT01590589). Data were accessed as part of European Huntington's Disease Network (EHDN) data mining project 0791. Ethical approval for REGISTRY was obtained in each participating country. All participants gave written informed consent.

Participant data

HD participant data, collected June 2004 - February 2016 across 161 sites in 17 European countries, was obtained for 6316 individuals (accessed October 2016) who had clinical HD onset, determined by the rating clinician in REGISTRY, and a confirmed pathogenic CAG length of 36-93 CAGs. Of these CAG sizes, 5027 were centrally determined by BioRep Inc. (Milan, Italy; REGISTRY protocols) and 1289 were derived by local diagnostic laboratories. Two estimates of the age at onset of symptoms and/or signs in HD were used in this study. First, the clinician-estimated age at first HD manifestation based upon all available clinical evidence at the first REGISTRY visit (coded as 'sxrater'). Having a 'sxrater' age at onset was required for inclusion in this study. Onset type was classified as motor, cognitive, psychiatric, oculomotor, other or mixed. As the clinician's estimate was given as a date, age estimates were calculated using the participant's anonymised birthday; where only a year was given, July 15th was used for estimation (15/07/xxxx). Second, the ages at onset of different symptoms in HD patients were estimated by the HD Clinical Characteristics Questionnaire (HD-CCQ) which was completed by a healthcare

professional, usually a HD-specialist nurse or similarly-qualified person, using responses from the individual with HD and their care partners (present in clinic in 93.1% of cases), and patient medical notes. The HD-CCQ comprises questions about eight symptoms commonly observed in HD, asking whether the participant has ever had the symptom (yes or no), and, if yes, the age at which the symptom was first experienced (Appendix 3). Information was available, at least in part, for 5609 individuals. The symptoms recorded (number of individuals with data) were: motor (chorea or other, consistent with HD; 5603), cognitive impairment sufficient to impact on work or daily living (5591), apathy (5584), depression (5595), perseverative/obsessive behaviour (5588), irritability (5586), violent or aggressive behaviour (5586) and psychosis (5589). For subsequent analyses, missing data were handled using pairwise deletion to maximise the number of individuals. Typically, the rater estimate of clinical onset and initial HD-CCQ would be recorded at the first REGISTRY visit, sometimes by one clinician, and sometimes by a clinician and another qualified staff member such as HD-specialist nurse, depending on local clinic set-up. Subsequent visits updated the HD-CCQ: we used data from the most recent clinic visit. We had data on Shoulson-Fahn disease stage at last clinic visit for 4554 individuals (72.1% of our study population): stage 1 (Total Functional Capacity (TFC) 11-13; N=890; 19.5%), stage 2 (TFC 7-10; N=1278; 28.1%), stage 3 (TFC 4-6; N=969; 21.3%), stage 4 (TFC 1-3; N=1133; 24.9%), stage 5 (TFC 0; N=284; 6.2%).

The Hospital Anxiety/Depression Scale (HADS) and Snaith Irritability Scale (SIS) were completed by the participant at each clinic visit and provide measures of anxiety, depression and irritability at that specific time. We used lifetime highest total

depression and total irritability scores from both the HADS and the SIS in analyses. Similarly, the symbol-digit modalities test (SDMT) and Stroop tests of cognitive ability were administered as part of the Unified Huntington's Disease Rating Scale (UHDRS)[11] at each visit. The UHDRS consists of validated questionnaires, tools and examinations related to motor, cognitive, behavioural and functional impairments seen in HD. For the SDMT and Stroop, we used the total correct scores from the most recent clinic visit. Disease duration was estimated by taking the most recent visit and subtracting the clinician's estimate of disease onset. The product of Problem Behaviours Assessment (PBA-s) severity and frequency scores from the most recent clinic was used for modelling purposes.

Statistical analyses of clinical data

Total depression scores from HADS, total irritability scores from SIS, the number of correct answers in the SDMT, the number of correct answers in Stroop tests or composite PBA-s scores were regressed on HD clinical characteristics data, age, CAG length, sex and disease duration (table 1). To calculate coefficients of determination (R^2 values, table 2), HD-CCQ age at onset data were natural log transformed. Only individuals with a known sex and a symptom onset ≥3 years were considered, and a residual vs leverage plot identified one influential data point passing Cook's distance that was removed from all R^2 calculations. *P* values were calculated comparing male and female R^2 values using Fisher's transformation[12]. A chi-square test was used to test for differences in symptom frequency, derived from the yes/no component of the HD-CCQ, between males and females.

Associations between binary responses in the HD-CCQ (1; experienced the symptom and 0; symptom not experienced) and clinical covariates were tested using logistic regression. The covariates used were sex, CAG length, alcohol consumption (units per week), tobacco use (cigarettes per day), education (years of education), TFC score and total motor score (TMS). An additional analysis regressed the type of HD onset defined by the clinician, coded as a binary variable, on the clinician's onset or CAG length (table e-2, doi:10.5061/dryad.pk0p2ngkz). This analysis was restricted to HD participants with CAGs 36-59, to be consistent with figure 1 subgroups, and also to adult-onset HD individuals (≥20 years). We also tested whether symptom presence was associated with the length of the wild-type (6-35 CAGs) and expanded CAGs (36-93 CAGs) alleles in individuals of known sex, and for whom both CAG lengths were known (table e-3, doi:10.5061/dryad.pk0p2ngkz). 19 individuals with a coincident formal diagnosis of schizophrenia, schizotypal disorder or schizoaffective disorder (ICD-10 F20, F21 or F25) were excluded from all models, although it was not possible to formally exclude these symptoms being part of the HD phenotype. Statistical analysis used *R* (version 3.6.0; R core team, 2019, https://www.r-project.org/).

Data availability

Further information and data requests should be directed to Thomas H. Massey (MasseyT1@cardiff.ac.uk). Anonymised summary data is available to qualified investigators. Furthermore, anonymised patient data is available from the European Huntington's Disease Network (EHDN) upon request given institutional assurance patient confidentiality will be upheld, and no attempt will be made to discover the identity of patients.

Results

The initial manifestation of HD varies with age and CAG length

The age at onset of the first unequivocal motor features of HD ('motor onset') has been used as a specific milestone in the natural history of HD in individuals, although it is only a crude measure of a progressive neuropathological process. It has proven particularly useful in recent genetic modifier studies of HD[13,14]. The first psychiatric and cognitive manifestations of HD are more difficult to define with certainty, being less specific for HD and clinically indistinguishable from common coincident psychiatric diagnoses (e.g. depression), particularly in younger patients many years from predicted motor onset. The timing of the first unequivocal feature of HD is typically retrospectively recorded by a rating physician in observational studies such as REGISTRY, based on clinical information and symptom history from patients and care partners[9,15,16]. The rater also records the initial major presenting feature out of a choice of six: motor, cognitive, psychiatric, oculomotor, other or mixed. We analysed the initial manifestation of HD for 6316 participants in REGISTRY[9], including 3083 males (48.8%) and 3233 females (51.2%). All participants had a confirmed genetic diagnosis of HD with a pathogenic CAG repeat length of 36-93 (figure e-1, doi:10.5061/dryad.pk0p2ngkz). The first manifestation of HD, determined by the rating physician, varied with patient age (figure 1A and table e-1, doi:10.5061/dryad.pk0p2ngkz). Individuals with onset before the age of 20, defined as juvenile HD, were equally likely to present with motor (24.5%), cognitive (21.8%) or psychiatric features (28.2%). In contrast, the initial manifestation of HD was more likely to be motor than psychiatric in adult-onset HD. As age at first manifestation increased (figure 1A and table e-2A, doi:10.5061/dryad.pk0p2ngkz) motor

presentations became more likely (odds ratio (OR) = 1.06 per ten year increase in onset age, 95% confidence interval (CI) 1.04-1.07; $P = 7.4 \times 10^{-22}$) but psychiatric presentations became less likely (OR = 0.96 per ten year increase in onset age, 95% CI 0.95-0.97; $P = 9.4 \times 10^{-16}$). For people presenting over the age of 60, over two-thirds (68.6%) had initial motor abnormalities with far fewer having psychiatric (11.5%) or cognitive (6.7%) presentations. Next, we tested whether there was any relationship between pathogenic CAG repeat length, known to be inversely correlated with age at clinical onset, and the presenting phenotype. Interestingly, there was no significant relationship between CAG length (36-59 inclusive) and the relative proportions of motor, cognitive and psychiatric onset cases (figure 1B and table e-2B, doi:10.5061/dryad.pk0p2ngkz). For the few cases with data and repeat lengths of more than 59 CAG we observed a more balanced distribution of motor, cognitive and psychiatric presentations, mirroring the trends seen for the juvenile HD cases.

Psychiatric and cognitive symptoms captured by the Clinical Characteristics Questionnaire correlate with scores from validated clinical tools

The HD Clinical Characteristics Questionnaire (HD-CCQ) was introduced to later versions of REGISTRY as the best retrospective way of capturing symptom data in existing HD populations. It is completed by a healthcare professional using information from individuals with HD and their care partners, present in clinic for over 93%, about lifetime history and age at onset of eight symptoms typical of HD. These symptoms are motor (compatible with HD), depression, irritability, violent or aggressive behavior, apathy, perseverative/obsessive behavior, psychosis and cognitive impairment sufficient to impact on work or daily living. In REGISTRY, this

information was updated at each annual clinic visit. In HD-CCQ, motor symptoms are not specified beyond being compatible with HD, limiting the utility of motor data, but psychiatric and behavioral symptoms are clearly defined.

Since prevalence data from HD-CCQ have not been used in large analyses before we first tested how well they correlated with validated clinical scores of depression (HADS), irritability (SIS) and cognition (SDMT and Stroop). To mitigate against potential effects of medication at certain times, we used the lifetime highest total depression and total irritability scores for each individual. For cognitive tests we used scores at the last recorded clinic visit as these would be expected to worsen progressively and be little affected by medication. Total depression score from HADS was significantly increased in individuals with depression recorded in HD-CCQ (table 1; increase of 1.49 units, 95% CI 1.09-1.89; $P = 5.7 \times 10^{-13}$). An increase in HADS score was also observed in individuals with HD-CCQ apathy, probably because apathy, common in HD, may be mistaken for depression by individuals and their care partners when completing the HD-CCQ. Total irritability score from SIS was significantly increased in individuals with HD-CCQ irritability (increase of 1.82 units, 95% CI 1.37-2.27; $P = 2.0 \times 10^{-15}$), and also with violent/aggressive behaviour (increase of 1.57 units, 95% CI 1.08-2.06; $P = 3.3 \times 10^{-10}$), as expected. Both SDMT and Stroop scores of cognitive ability were significantly decreased in individuals with cognitive impairment as recorded in HD-CCQ (reductions of 3.52 units, 95% CI 2.71-4.33; $P = 2.3 \times 10^{-17}$ and 3.41 units, 95% CI 2-65-4.17; $P = 1.4 \times 10^{-22}$, respectively). Significant associations between cognitive scores and motor and apathy symptoms were also observed. In addition, we found robust and specific associations between neuropsychiatric symptoms recorded in HD-CCQ and their related symptoms scored

using the validated short-form Problem Behaviors Assessment (PBA-s; supplemental table e-4, doi:10.5061/dryad.pk0p2ngkz). The specificity of the associations between HD-CCQ data and recognised clinical scales validated the use of HD-CCQ data in subsequent analyses.

Psychiatric symptoms are common in HD gene carriers and are associated with CAG repeat length

We next analysed the lifetime prevalence of the eight symptoms recorded in HD-CCQ in 5609 individuals with HD at their most recent clinic visit (table 2). The mean age at last recorded clinic visit was 53.3 years; 53.5 years for males with data (range 10.4 – 92.6 years; N = 2569) and 53.2 years for females (range 7.9 – 90.2 years; N = 2698). Almost all (>99%) had experienced motor symptoms compatible with HD, indicating why motor abnormalities remain the diagnostic standard for clinical onset of HD. Although motor symptoms are not defined explicitly in HD-CCQ, contemporaneous data from UHDRS showed that 96.8% of our study population had chorea, alongside variable amounts of incoordination, dystonia and rigidity. In HD gene carriers these motor symptoms are likely to be specific manifestations of HD. The next most prevalent symptom was depression, occurring in 64.5% of HD individuals with significantly more females affected than males (70.4% vs 58.2%; OR 1.70, 95% CI 1.52-1.90; $P = 2.6 \times 10^{-21}$). Cognitive impairment sufficient to impact upon work or activities of daily living, apathy and irritability were also each observed in over half of our HD population. Cognitive impairment and apathy were equally likely in males and females, but there was significantly more irritability observed in males (62.9% vs 56.9%; OR 0.78, 95% CI 0.70-0.87; $P = 4.0 \times 10^{-6}$). An excess of violent or aggressive behaviour was also observed in the male group (34.9% vs

27.0%; OR 0.69, 95% CI 0.62-0.77; $P = 2.0 \times 10^{-10}$). Psychosis was the least prevalent of the eight recorded symptoms, although this was still observed in over 11% of individuals with HD with no significant difference in prevalence between males and females.

There was a strong inverse correlation between pathogenic CAG repeat length (40-55 CAG inclusive) and mean age at symptom onset for all symptoms analysed (figure 2). We found no effect of wild-type CAG allele length on any symptom onset, nor any significant statistical interaction between expanded and wild-type repeat lengths (table e-3, doi:10.5061/dryad.pk0p2ngkz). Pathogenic CAG length explained 66.3% of the variance in age at onset of motor symptoms, in line with previous estimates[2,3,17–23], but also between 37.5% and 61.9% of the variance in onset of each of the psychiatric symptoms analysed (table 2). Depression had the weakest association with CAG repeat length (R^2 = 37.5%). CAG length accounted for significantly more of the variance in age at onset of perseverative/obsessive behaviour in males (table 2; $P = 3.7 \times 10^{-3}$) and irritability in females ($P = 1.3 \times 10^{-3}$).

The timing of motor and psychiatric symptoms in HD gene carriers varies with symptom type and CAG length

Given that motor onset is often used as a specific milestone in the natural history of HD, we investigated the timing of each of the seven psychiatric/cognitive symptoms relative to the age at first motor symptoms recorded in HD-CCQ (figure 2). The differences in ages between first motor symptoms and each of the psychiatric symptoms were approximately normally distributed, with a wide range of at least +/- 20 years in each case (figures 2 and e-2, doi:10.5061/dryad.pk0p2ngkz). In those patients reporting depression, onset occurred before motor symptoms in 39.2% (N=

1369/3495). For patients with irritability, onset occurred before motor symptoms in 30.8% (N= 996/3235). Perseverative/obsessive behaviour tended to occur later in the disease course, after motor symptoms, as did psychosis although numbers were smaller. Cognitive impairment and apathy had the most positively skewed distributions with onset occurring after motor onset in 2179/3225 (67.6%) and 1981/2852 (69.5%) of individuals, respectively. Overall, 42.4% of HD patients (N= 2140/5042) reported at least one psychiatric or cognitive symptom in advance of motor symptoms, with a further 22.3% (N= 1126/5042) reporting at least one of these symptoms at the same time as motor abnormalities.

We next assessed whether there were any patterns in the mean ages of onset of the different symptoms when plotted by CAG repeat length (figure 3). Some consistent relationships between symptoms were observed. Depression usually had the youngest mean age at onset, followed by motor impairment and then apathy and cognitive impairment as the latest symptoms. Mean age at onset of irritability preceded that of motor onset at shorter repeat lengths (40-43 CAGs, inclusive) but tended to follow it at longer repeat lengths (44-53 CAGs, inclusive). The mean difference in years from onset of first symptom to last decreased with CAG repeat length from approximately 8 years for 40 repeats to 4 years for 55 repeats (figure 3).

Cognitive and psychiatric symptoms are significantly associated with reduced functional capacity

To assess whether psychiatric, cognitive or motor symptoms were associated with altered functional abilities we used multiple logistic regression (table 4). This analysis incorporated sex, pathogenic CAG length, duration of disease from clinical onset to

last clinic visit, alcohol consumption, tobacco use, educational attainment, total functional capacity score and total motor score as predictors of the presence/absence of each HD-CCQ symptom. The presence of any of the psychiatric or cognitive symptoms was significantly associated with lower total functional capacity (TFC), an indication of impaired ability to work, manage personal finances and function independently. Cognitive impairment was most significantly associated with reduced TFC (OR per unit decrease in TFC = 1.28, 95% CI 1.23-1.35; $P = 1.6 \times 10^{-25}$). Depression was significantly associated with lower total motor scores (indicating fewer motor symptoms or signs), fitting with its prevalence early in the disease course. Finally, significant associations were observed between depression and female sex (OR = 1.77, 95% CI 1.44-2.17; $P = 7.0 \times 10^{-8}$) and tobacco use and irritability (OR per extra cigarette per day = 1.02, 95% CI 1.01-1.03; $P = 1.0 \times 10^{-4}$). Although not reaching strict criteria for significance after correcting for multiple tests, associations were also found between male sex and irritability (OR = 0.75, 95% CI 0.61-0.92; $P = 5.4 \times 10^{-3}$) and lower educational attainment and psychosis (OR per extra year of education = 0.92, 95% CI 0.88-0.97; $P = 2.2 \times 10^{-3}$).

Discussion

In this large study of over 6000 patients we have shown that the initial manifestation of HD, as determined retrospectively by an expert rater, varies significantly with age. Late presentations (>60 years) are usually associated with motor abnormalities, whereas early presentations (<20 years; juvenile HD) are associated with a wider range of motor, cognitive and psychiatric abnormalities (figure 1A). These results extend prior studies which have shown that motor presentation of HD is common in late-onset disease (65.5% of an earlier REGISTRY cohort[24]), with more variable presentations in juvenile HD[25,26]. Approximately 20% of HD patients present with rater-determined psychiatric features, in line with previous findings (table e-1, doi:10.5061/dryad.pk0p2ngkz)[9]. Cognitive onset of HD might be under-reported in older age-groups due to it being regarded as coincident 'age-related' change. Importantly, our results show there is little relationship between pathogenic CAG repeat length and onset type in adult-onset HD (figure 1B), despite both being associated with age at clinical onset. These data fit a model in which age at clinical onset is driven primarily by CAG repeat length, but modified by environmental factors and variants at other genomic loci[14,23,27,28]. The age and physiology of the brain at clinical onset subsequently determines the types of symptoms that become manifest.

The HD-CCQ captures quantitative information not available elsewhere on symptom prevalence and timing in the HD population. Prior to its introduction in REGISTRY, age at first motor symptoms was not routinely recorded for all HD patients. HD-CCQ provides particular insight into neuropsychiatric symptoms but is not designed to capture the subtle early motor or cognitive signs found in prospective studies[7,8]. As it relies on retrospective reporting by patients and care partners the HD-CCQ is necessarily coarse, although the data it generates correlate well with more precise

measures of depression, irritability and cognition (table 1). Cognitive impairment measured by SDMT or Stroop correlated most strongly with lifetime history of cognitive impairment in HD-CCQ, as expected, but also showed significant correlations with motor symptoms and apathy. These results fit with other studies showing that these symptoms track together in the disease trajectory[29,30]. There was also a significant association between cognitive impairment and psychosis, which fits the cognitive deficits observed in schizophrenia[31]. Conversely, validated depression and irritability scores correlated well with their respective prevalence data from HD-CCQ but were not associated with motor or cognitive impairment (table 1).

Almost all HD patients have specific motor abnormalities consistent with HD during their disease course (table 2). Psychiatric and cognitive symptoms are also very common (table 2), much more prevalent than in non-HD populations[5,10,32,33], and likely underestimated due to pathological unawareness of these traits by HD patients[34]. However, clinically it is currently impossible to distinguish between symptoms arising as a result of the HD mutation and those from primary psychiatric disorders, particularly in younger pre-manifest patients in whom diseases such as depression are common[35]. Furthermore, environmental effects on mental health, such as living in a family with HD, should not be overlooked. As such, non-motor symptoms should not be used to make a clinical diagnosis of HD and this could even cause harm in vulnerable individuals with psychiatric symptoms. Future studies of psychiatric and cognitive symptoms and signs in HD gene carriers against gene-negative community controls might help define a HD-specific neuropsychiatric phenotype that would enable more confident attribution of early abnormalities to HD.

The age at onset of each symptom recorded by HD-CCQ was inversely correlated with CAG length (figure 3), with motor symptoms best correlated (table 3).

Depression was least correlated (R^2 = 37.5%), likely reflecting the high prevalence of the symptom in the general population independent of HD and the lack of use of universal diagnostic criteria. These data are consistent with previous reports showing that CAG length accounts for 47-72% of the variance in age at motor onset of HD[36], but contradict previous studies that reported no correlation between CAG repeat length and psychiatric symptoms[37–40]. However, these studies were small and often examined incident psychiatric symptoms, which can fluctuate over time, rather than lifetime history as here. Increasingly accurate CAG tract sizing will improve the accuracy of correlations between repeat length and symptoms[14,41,42].

Despite considerable variation in the timing of psychiatric and motor symptoms, there are some conserved patterns (figures 2 & 3). Depression, and less often irritability, can precede motor symptoms by many years. Conversely, apathy and cognitive impairment tend to occur after motor symptoms, although patients do recognise and report these symptoms less readily than depression or irritability. Overall, the HD-CCQ data show that 64.8% of our HD population (N = 3266/5042) reported at least one psychiatric or cognitive symptom by the time of first motor symptoms. This is a much higher figure than previously reported based on clinician estimates of first HD manifestation (figure 1)[9], most likely because it is difficult to confidently attribute early psychiatric symptoms to HD. The overlap between HD and psychiatric disorders has been demonstrated by the recent finding that polygenic risk scores for psychiatric diseases, particularly depression and schizophrenia, are associated with increased risk of corresponding psychiatric symptoms in HD[29]. This suggests that the expanded *HTT* CAG repeat might lower the genetic threshold for manifestation of typical psychiatric symptoms[29]. In agreement, we found the expected relationships between female sex and depression and male sex and

irritability in our cohort (table 4). The nominally significant negative association of psychosis in HD with educational level (table 4) also corroborates work showing that higher levels of education are associated with decreased schizophrenia risk[43].

We acknowledge several potential limitations of these data: they are retrospective, subject to recall bias, and cross-sectional. Furthermore, HD-CCQ data depend on the interpretation of questions: for example, 'motor symptoms' are not explicitly defined and so although 96.8% of our population had chorea this was not documented in HD-CCQ. Future iterations might usefully subdivide 'motor symptoms' into (1) fidgety or jerky involuntary movements (chorea)' and (2) other HD-related movement problems such as unsteadiness, stiffness or trouble with fine movements. Our analyses are based on data from the most recent clinic visit which is at different points of the disease course in different individuals. We controlled for this by using disease duration, the time between first onset and last clinic visit, as a covariate in analyses. The use of psychoactive medications is found in up to 60% of HD patients and might confound motor and neuropsychiatric phenotypes[9,44]. Of drugs prescribed for chorea, tetrabenazine can induce depression and antipsychotics can reduce irritability. They also suppress motor manifestations which might affect the total motor scores used here as a co-variate (table 4). It is hard to control for these effects. Drugs prescribed to treat symptoms once they are present will not influence symptom onset data. We used worst-ever depression and irritability scores when validating the use of HD-CCQ to mitigate against the effects of medication prescribed at certain times.

Previous prospective studies of phenotype in HD such as PREDICT-HD and TRACK-HD have shown subtle early reductions in psychiatric and cognitive function years in advance of clinical onset[7,8]. The HD-CCQ accesses retrospective data from

large existing populations of manifest HD patients and shows similar trends. Since the HD-CCQ is part of ongoing longitudinal observational studies such as ENROLL-HD, future analyses of larger populations will be possible and of benefit. The presence of psychiatric and cognitive symptoms in HD gene carriers is associated with significantly reduced functional capacity, emphasizing the importance of early recognition and management of these symptoms[45,46]. Although recent models of HD staging and progression do not directly include psychiatric and cognitive symptoms[47–49], work is underway to include them in ongoing observational studies and clinical trials to improve the accuracy of clinical outcome measures.

Acknowledgments

We thank all the patients who contributed data to this research. B.Mc. was supported by a PhD studentship from Cardiff University School of Medicine. J.F.G. and M.E.M. received support from NIH grant NS091161 and from the CHDI Foundation, Inc. J-M.L. received support from grant R01NE-105709. A.E.R. received support from MRC, Wellcome Trust, Campaign for Alzheimer's Research in Europe, Horizon 2020, JPND and Health and Care Research Wales. L.J., N.M.W. and P.H. were supported by an MRC Centre grant (MR/L010305/1). T.H.M. was supported by a Welsh Clinical Academic Track Fellowship, an MRC Clinical Training Fellowship (MR/P001629/1) and a Patrick Berthoud Charitable Trust Fellowship through the Association of British Neurologists.

Financial Disclosures of all authors (for the preceding 12 months)

J.F.G.: Scientific Advisory Board member and has a financial interest in Triplet Therapeutics, Inc. His NIH-funded project is using genetic and genomic approaches to uncover other genes that significantly influence when diagnosable symptoms emerge and how rapidly they worsen in Huntington Disease. The company is developing new therapeutic approaches to address triplet repeat disorders such Huntington's Disease, Myotonic Dystrophy and spinocerebellar ataxias. His interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies.

G.B.L.: Consulting services, advisory board functions, clinical trial services and/or lectures for Allergan, Alnylam, Amarin, AOP Orphan Pharmaceuticals AG, Bayer Pharma AG, CHDI Foundation, GlaxoSmithKline, Hoffmann-LaRoche, Ipsen, ISIS Pharma, Lundbeck, Neurosearch Inc, Medesis, Medivation, Medtronic, NeuraMetrix, Novartis, Pfizer, Prana Biotechnology, Sangamo/Shire, Siena Biotech, Temmler Pharma GmbH and Teva Pharmaceuticals. He has received research grant support from the CHDI Foundation, the Bundesministerium für Bildung und Forschung (BMBF), the Deutsche Forschungsgemeinschaft (DFG), the European Commission (EU-FP7, JPND). His study site Ulm has received compensation in the context of the observational Enroll-HD Study, TEVA, ISIS and Hoffmann-Roche and the Gossweiler Foundation. He receives royalties from the Oxford University Press and is employed by the State of Baden-Württemberg at the University of Ulm.

A.E.R.: Chair of European Huntington's Disease Network (EHDN) executive committee, Global PI for Triplet Therapeutics

L.J. is a member of the scientific advisory boards of LoQus23 Therapeutics and Triplet Therapeutics and has received grant support from CHDI.

T.H.M. is an associate member of the scientific advisory board of LoQus23 Therapeutics.

B.Mc., J-M.L., M.E.M., M.O., N.M.W., P.H.: nothing to disclose

Appendix 1 – Authors

Name	Location	Contribution/Role
Branduff McAllister, BSc, PhD	Cardiff University, Cardiff, UK	Organized data; Designed and executed statistical analyses; Wrote first paper draft; Reviewed and critiqued paper manuscript
James F. Gusella, PhD	Massachusetts General Hospital, Boston, USA	Reviewed and critiqued paper manuscript
Bernhard Landwehrmeyer, MD, PhD	University of Ulm, Ulm, Germany	Reviewed and critiqued paper manuscript
Jong-Min Lee, PhD	Massachusetts General Hospital, Boston, USA	Reviewed and critiqued paper manuscript
Marcy E. MacDonald, PhD	Massachusetts General Hospital, Boston, USA	Reviewed and critiqued paper manuscript
Michael Orth, MD, PhD	Swiss Huntington's disease Centre, Bern, Switzerland	Reviewed and critiqued paper manuscript
Anne E. Rosser, MB BChir, FRCP, PhD	Cardiff University, Cardiff, UK	Reviewed and critiqued paper manuscript
Nigel M. Williams, BSc, PhD	Cardiff University, Cardiff, UK	Reviewed and critiqued paper manuscript
Peter Holmans, BA, PhD	Cardiff University, Cardiff, UK	Designed and conceptualized study; Designed and critiqued statistical analyses; Reviewed and critiqued paper manuscript
Lesley Jones, BSc, PhD (*)	Cardiff University, Cardiff, UK	Designed and conceptualized study; Wrote first paper draft; Reviewed and critiqued paper manuscript
Thomas H. Massey, MA, BM Bch, DPhil (*), (†)	Cardiff University, Cardiff, UK	Designed and conceptualized study; Wrote first paper draft; Reviewed and critiqued paper manuscript

(*) indicates corresponding authors

(†) indicates the principal investigator

Appendix 2 – Co-investigators of the European Huntington's Disease Network REGISTRY Study

Name	Location	Contribution/Role
Raphael M. Bonelli	1,3	Site Investigator, REGISTRY Steering Committee
Karen Hecht	1	Site Investigator
Brigitte Herranhof	1	Site Investigator
Anna Holl (formerly Hödl)	1	Site Investigator
Hans-Peter Kapfhammer	1	Site Investigator
Michael Koppitz	1	Site Investigator
Sabine Lilek	1	Site Investigator
Markus Magnet	1	Site Investigator
Nicole Müller	1	Site Investigator
Daniela Otti	1	Site Investigator
Annamaria Painold	1	Site Investigator
Karin Reisinger	1	Site Investigator
Monika Scheibl	1	Site Investigator
Helmut Schöggl	1	Site Investigator
Jasmin Ullah	1,40	Site Investigator
Eva-Maria Braunwarth	2	Site Investigator
Florian Brugger	2	Site Investigator
Lisa Buratti	2	Site Investigator
Eva-Maria Hametner	2	Site Investigator
Caroline Hepperger	2	Site Investigator
Christiane Holas	2	Site Investigator
Anna Hotter	2	Site Investigator
Anna Hussl	2	Site Investigator
Barbara Larcher	2	Site Investigator
Philipp Mahlknecht	2	Site Investigator
Christoph Müller	2	Site Investigator
Bernadette Pinter	2	Site Investigator
Werner Poewe	2	Site Investigator
Eva-Magdalena Reiter	2	Site Investigator
Klaus Seppi	2	Site Investigator
Fabienne Sprenger	2	Site Investigator
Gregor Wenning	2	Site Investigator
Gunther Ladurner	3	Site Investigator
Stefan Lilek	3	Site Investigator
Daniela Sinadinosa	3	Site Investigator
Wolfgang Staffen	3	Site Investigator
Anna Maria Walleczek	3	Site Investigator

Name	Location	Contribution/Role
Christoph Linder	4	Site Investigator
Walter Pirker	4	Site Investigator
Dirk Liessens	5	Site Investigator
Godelinde Calmeyn	5	Site Investigator
Nele Somers	5	Site Investigator
Isabelle Delvaux	5	Site Investigator
Andrea Boogaerts	5,10	Site Investigator
Anja Flamez	6	Site Investigator
Sylvie de Raedt	6	Site Investigator
Nick Alaerts	7	Site Investigator
Hichem Slama	7	Site Investigator
Frédéric Supiot	7	Site Investigator
Eric Constant	8	Site Investigator
Anne-Françoise Gillardin	8	Site Investigator
Marie-Claude Léonard	8	Site Investigator
Christine Verellen-Dumoulin	8,9	Site Investigator, REGISTRY Steering Committee
Françoise van de Wyngaerde	8	Site Investigator
Michel Dupuis	9	Site Investigator
Cécile Minet	9	Site Investigator
Pascale Ribaï	9	Site Investigator
Dominique Van Paemel	9	Site Investigator
Wim Vandenberghe	10	Site Investigator, REGISTRY Steering Committee
Dimphna van Reijen	10	Site Investigator
Petra Weckx	10	Site Investigator
Michaela Kaiserova	11	Site Investigator
Zuzana Šenkárová	11	Site Investigator
Ondřej Bezdíček	12	Site Investigator
Jiří Klempíř	12,166	Site Investigator, REGISTRY Steering Committee
Olga Klempířová	12	Site Investigator
Veronika Majerová-Ibarburu	12	Site Investigator
Tomáš Nikolai	12	Site Investigator
Jan Roth	12	Site Investigator
Irena Stárková	12	Site Investigator
Louise Hasselstrøm Madsen	13	Site Investigator
Anette Torvin Møller	13	Site Investigator
Lena Hjermind	14	Site Investigator
Oda Jacobsen	14	Site Investigator

Name	Location	Contribution/Role
Ida Unmack Larsen	14	Site Investigator
Suzanne Lindquist	14	Site Investigator
Jørgen E. Nielsen	14	Site Investigator, REGISTRY Steering Committee
Lisbeth Regeur	14	Site Investigator
Peter Roos	14	Site Investigator
Jette Stockholm	14	Site Investigator
Christina Vangsted-Hansen	14	Site Investigator
Tua Vinther-Jensen	14	Site Investigator
Annette Lolk	15	Site Investigator
Marianne Lundsgaard	15	Site Investigator
Lene Wermuth	15	Site Investigator
Christian Andersson	16	Site Investigator
Clara Nyberg	16	Site Investigator
Jimmy Sundblom	16,121	Site Investigator
Maarit Peippo	17	Site Investigator
Marjatta Sipponen	17	Site Investigator
Anu Bruun	18	Site Investigator
Paivi Hartikainen	18	Site Investigator
Seija Mäkipää	18	Site Investigator
Mari Ollokainen	18	Site Investigator
Jaana Åman	19	Site Investigator
Mikko Kärppä	19	Site Investigator
Jaakko Ignatius	20	Site Investigator
Outi Jääskeläinen	20	Site Investigator
Outi Kajula	20	Site Investigator
Jukka Moilanen	20	Site Investigator
Aki Mustonen	20	Site Investigator
Maire Santala	21	Site Investigator
Pia Eklund	22	Site Investigator
Heli Hiivola	22	Site Investigator
Hannele Hyppönen	22	Site Investigator
Kirsti Martikainen	22	Site Investigator
Marjut Ojala	22	Site Investigator
Sirkku Tähkäpää	22	Site Investigator
Katri Tuuha	22	Site Investigator
Philippe Allain	23	Site Investigator
Dominique Bonneau	23	Site Investigator

Name	Location	Contribution/Role
Marie Bost	23	Site Investigator
Bénédicte Gohier	23	Site Investigator
Marie-Anne Guérid	23	Site Investigator
Audrey Olivier	23	Site Investigator
Julie Prouzet	23	Site Investigator
Adriana Prundean	23	Site Investigator
Clarisse Scherer-Gagou	23	Site Investigator
Christophe Verny	23	Site Investigator
Blandine Babiloni	24	Site Investigator
Déborah Bled	24	Site Investigator
Sabrina Debruxelles	24	Site Investigator
Charlotte Duché	24	Site Investigator
Sonia Fraisse	24	Site Investigator
Cyril Goizet	24	Site Investigator
Laetitia Jameau	24	Site Investigator
Danielle Lafoucrière	24	Site Investigator
Umberto Spampinato	24	Site Investigator
Julien Couttier	25	Site Investigator
Bérengère Debilly	25	Site Investigator
Christine Delaigue	25	Site Investigator
Philippe Derost	25	Site Investigator
Franck Durif	25	Site Investigator
Véronique Germain	25	Site Investigator
Perrine Legendre	25	Site Investigator
Sylvie Loiseau	25	Site Investigator
Ana Marques	25	Site Investigator
Miguel Ulla	25	Site Investigator
Tiphaine Vidal	25	Site Investigator
Anne-Catherine Bachoud-Lévi	26	Site Investigator, REGISTRY Steering Committee
Farideh Badei	26	Site Investigator
Marie-Françoise Boissé	26	Site Investigator
Lotfi Boudali	26	Site Investigator
Laurent Cleret de Langavant	26	Site Investigator
Laurie Lemoine	26	Site Investigator
Graca Morgado	26	Site Investigator
Katia Youssov	26	Site Investigator
Agnès Annic	27	Site Investigator

Name	Location	Contribution/Role
Recka Barthélémy	27	Site Investigator
Christelle De Bruycker	27	Site Investigator
Maryline Cabaret	27	Site Investigator
Anne-Sophie Carette	27	Site Investigator
Nicolas Carrière	27	Site Investigator
Eric Decorte	27	Site Investigator
Luc Defebvre	27	Site Investigator
Marie Delliaux	27	Site Investigator
Arnaud Delval	27	Site Investigator
Alizé Depelchin	27	Site Investigator
Alain Destee	27	Site Investigator
Nelly Dewulf-Pasz	27	Site Investigator
Thibaut Dondaine	27	Site Investigator
Florence Dugauquier	27	Site Investigator
Kathy Dujardin	27	Site Investigator
Lucie Hopes	27	Site Investigator
Pierre Krystkowiak	27,28	Site Investigator
Marie-Hélène Lemaire	27	Site Investigator
Sylvie Manouvrier	27	Site Investigator
Eugénie Mutez	27	Site Investigator
Mireille Peter	27	Site Investigator
Lucie Plomhause	27	Site Investigator
Bernard Sablonnière	27	Site Investigator
Clémence Simonin	27	Site Investigator
Céline Tard	27	Site Investigator
Stéphanie Thibault-Tanchou	27	Site Investigator
Isabelle Vuillaume	27	Site Investigator
Marcellin Bellonet	28	Site Investigator
Stéphanie Blin	28	Site Investigator
Simone Chen	28	Site Investigator
Kamel Masmoudi	28	Site Investigator
Gilles Morin	28	Site Investigator
Martine Roussel	28	Site Investigator
Mélissa Tir	28	Site Investigator
Béatrice Schüler	28	Site Investigator
Sandrine Wannepain	28	Site Investigator
Yassine Zouitina	28	Site Investigator

Name	Location	Contribution/Role
Jean-Philippe Azulay	29	Site Investigator
Marie Delfini	29	Site Investigator
Alexandre Eusebio	29	Site Investigator
Frédérique Fluchere	29	Site Investigator
Aicha Guenam	29	Site Investigator
Laura Mundler	29	Site Investigator
Karine Nguyen	29	Site Investigator
Sandra Benaich	30	Site Investigator
Alexis Brice	30	Site Investigator
Sarah Boster	30	Site Investigator
Perrine Charles	30	Site Investigator
Alexandra Durr	30	Site Investigator
Claire Ewenczyk	30	Site Investigator
Hélène Francisque	30	Site Investigator
Céline Jauffret	30	Site Investigator
Damian Justo	30	Site Investigator
Abdulrahman Kassar	30	Site Investigator
Stephan Klebe	30,51	Site Investigator
Fabien Lesne	30	Site Investigator
Paolo Milani	30	Site Investigator
Marie-Lorraine Monin	30	Site Investigator
Tiffany Monnier	30	Site Investigator
Emmanuel Roze	30	Site Investigator
Alina Tataru	30	Site Investigator
Maya Tchikviladzé	30	Site Investigator
Sandrine Bioux	31	Site Investigator
Evangeline Bliaux	31	Site Investigator
Carole Girard	31	Site Investigator
Lucie Guyant-Maréchal	31	Site Investigator
Didier Hannequin	31	Site Investigator
Véronique Hannier	31	Site Investigator
Séverine Jourdain	31	Site Investigator
David Maltête	31	Site Investigator
Dorothée Pouliquen	31	Site Investigator
Mathieu Anheim	32	Site Investigator
Nadia Barun	32	Site Investigator
Ouhaid Lagha-Boukbiza	32	Site Investigator

Name	Location	Contribution/Role
Nadine Longato	32	Site Investigator
Christophe Marcel	32	Site Investigator
Clélie Phillipps	32	Site Investigator
Gabrielle Rudolf	32	Site Investigator
Gisèle Steinmetz	32	Site Investigator
Christine Tranchant	32	Site Investigator
Caroline Wagner	32	Site Investigator
Marie-Agathe Zimmermann	32	Site Investigator
Leily Blondeau	33	Site Investigator
Fabienne Calvas	33	Site Investigator
Samia Cheriet	33	Site Investigator
Helène Delabaere	33	Site Investigator
Jean-François Demonet	33	Site Investigator
Laurent Marquine	33	Site Investigator
Jérémie Pariente	33	Site Investigator
Michèle Pierre	33	Site Investigator
Elsa Pomies	33	Site Investigator
Sandrine Rolland	33	Site Investigator
Corinne Souyris	33	Site Investigator
Christoph Michael Kosinski	34	Site Investigator
Eva Milkereit	34	Site Investigator
Daniela Probst	34	Site Investigator
Kathrin Reetz	34	Site Investigator
Christian Sass	34,48	Site Investigator
Johannes Schiefer	34	Site Investigator
Christiane Schlangen	34	Site Investigator
Cornelius J. Werner	34	Site Investigator
Markus Beuth	35	Site Investigator
Harald Gelderblom	35	Site Investigator
Josef Priller	35	Site Investigator
Harald Prüß	35	Site Investigator
Eike Spruth	35	Site Investigator
Silvia Thiel	35	Site Investigator
Jürgen Andrich	36	Site Investigator
Gisa Ellrichmann	36	Site Investigator
Lennard Herrmann	36	Site Investigator
Rainer Hoffmann	36	Site Investigator

Name	Location	Contribution/Role
Barbara Kaminski	36	Site Investigator
Peter Kraus	36	Site Investigator
Carsten Saft	36	Site Investigator, REGISTRY Steering Committee
Christiane Stamm	36	Site Investigator
Christos Ganos	37,42	Site Investigator
Lars Stubbe	37,42	Site Investigator
Vera Tadic	37	Site Investigator
Jennifer Tübing	37	Site Investigator
Herwig Lange	38,48	Site Investigator
Cecile Bosredon	39	Site Investigator
Ulrike Hunger	39	Site Investigator
Matthias Löhle	39	Site Investigator
Antonia Maass	39	Site Investigator
Christiana Ossig	39	Site Investigator
Simone Schmidt	39	Site Investigator
Alexander Storch	39	Site Investigator
Annett Wolz	39	Site Investigator
Martin Wolz	39	Site Investigator
Zacharias Kohl	40	Site Investigator
Christina Kozay	40	Site Investigator
Jürgen Winkler	40	Site Investigator
Ulrike Bergmann	41	Site Investigator
Regina Böringer	41	Site Investigator
Philipp Capetian	41	Site Investigator
Gerit Kammel	41	Site Investigator
Johann Lambeck	41	Site Investigator
Miriam Mächtel	41	Site Investigator
Simone Meier	41	Site Investigator
Michel Rijntjes	41	Site Investigator
Birgit Zucker	41	Site Investigator
Kai Boelmans	42	Site Investigator
Ines Goerendt	42	Site Investigator
Walburgis Heinicke	42	Site Investigator
Ute Hidding	42	Site Investigator
Jan Lewerenz	42,50	Site Investigator
Alexander Münchau	42	Site Investigator
Michael Orth	42,50	Site Investigator

Name	Location	Contribution/Role
Jenny Schmalfeld	42	Site Investigator
Simone Zittel	42	Site Investigator
Gabriele Diercks	43	Site Investigator
Dirk Dressler	43	Site Investigator
Flverly Francis	43	Site Investigator
Sabine Gayde-Stephan	43	Site Investigator
Heike Gorzolla	43	Site Investigator
Bianca Kramer	43	Site Investigator
Rebecca Minschke	43	Site Investigator
Christoph Schrader	43	Site Investigator
Pawel Tacik	43	Site Investigator
Michael Ribbat+	44	Site Investigator
Bernhard Longinus	45	Site Investigator
Carsten Möller	46	Site Investigator
Katrin Bürk	46	Site Investigator
Antje Lüsebrink	47	Site Investigator
Mark Mühlau	47	Site Investigator
Alexander Peinemann	47	Site Investigator
Michael Städtler	47	Site Investigator
Adolf Weindl	47	Site Investigator
Juliane Winkelmann	47	Site Investigator
Cornelia Ziegler	47	Site Investigator
Natalie Bechtel	48	Site Investigator
Heike Beckmann	48	Site Investigator
Stefan Bohlen	48	Site Investigator
Nicole Göpfert	48	Site Investigator
Eva Hölzner	48	Site Investigator
Ralf Reilmann	48	Site Investigator
Stefanie Rohm	48	Site Investigator
Silke Rumpf	48	Site Investigator
Sigrun Schepers	48	Site Investigator
Nathalia Weber	48	Site Investigator
Michael Bachmeier	49	Site Investigator
Matthias Dose	49	Site Investigator
Nina Hofstetter	49	Site Investigator
Ralf Marquard	49	Site Investigator
Alzbeta Mühlbäck	49	Site Investigator

Name	Location	Contribution/Role
Katrin Barth	50	Site Investigator
Andrea Buck	50	Site Investigator
Julia Connemann	50	Site Investigator
Daniel Ecker	50,163	Site Investigator, Language Coordinator
Carolin Geitner	50	Site Investigator
Christine Held	50,163	Site Investigator, Language Coordinator
Andrea Kesse	50	Site Investigator
G. Bernhard Landwehrmeyer	50	Site Investigator, REGISTRY Steering Committee
Franziska Lezius	50	Site Investigator
Solveig Nepper	50	Site Investigator
Anke Niess	50	Site Investigator
Ariane Schneider	50	Site Investigator
Daniela Schwenk	50	Site Investigator
Sigurd Süssmuth	50	Site Investigator
Sonja Trautmann	50	Site Investigator
Melanie Vogel	50	Site Investigator
Patrick Weydt	50	Site Investigator
Thomas Musacchio	51	Site Investigator
Christine Leypold	51	Site Investigator
Kerstin Nöth	51	Site Investigator
Claudia Cormio	52	Site Investigator
Olimpia Difruscolo	52	Site Investigator
Giovanni Franco	52	Site Investigator
Angela Nuzzi	52	Site Investigator
Vittorio Sciruicchio	52	Site Investigator
Claudia Serpino	52	Site Investigator
Marina de Tommaso	52	Site Investigator
Giovanna Calandra-Buonaura	53	Site Investigator
Sabina Capellari	53	Site Investigator
Pietro Cortelli	53	Site Investigator
Roberto Gallassi	53	Site Investigator
Roberto Poda	53	Site Investigator
Cesa Scaglione	53	Site Investigator
Chiara Agosti	54	Site Investigator
Sergio Barlati	54	Site Investigator
Silvia Compostella	54	Site Investigator
Eleonora Marchina	54	Site Investigator

Name	Location	Contribution/Role
Alessando Padovani	54	Site Investigator
Michela Figorilli	55	Site Investigator
Francesco Marrosu	55	Site Investigator
Antonella Muroni	55	Site Investigator
Valeria Piras	55	Site Investigator
Melisa Vacca	55	Site Investigator
Elisabetta Bertini	56	Site Investigator
Caterina Bartoli	56	Site Investigator
Fernanda Fortunato	56	Site Investigator
Elena Ghelli	56	Site Investigator
Andrea Ginestroni	56	Site Investigator
Claudia Mechi	56	Site Investigator
Marco Paganini	56	Site Investigator
Silvia Piacentini	56	Site Investigator
Silvia Pradella	56	Site Investigator
Anna Maria Romoli	56	Site Investigator
Sandro Sorbi	56	Site Investigator
Giovanni Abbruzzese	57	Site Investigator
Monica Bandettini di Poggio	57	Site Investigator
Giovanna Ferrandes	57	Site Investigator
Paola Mandich	57	Site Investigator
Roberta Marchese	57	Site Investigator
Emilio Di Maria	57	Site Investigator
Tiziano Tamburini	57	Site Investigator
Alberto Albanese	58	Site Investigator
Simona Castagliuolo	58	Site Investigator
Anna Castaldo	58	Site Investigator
Stefano Di Donato	58	Site Investigator
Daniela Di Bella	58	Site Investigator
Cinzia Gellera	58	Site Investigator
Silvia Genitrini	58	Site Investigator
Caterina Mariotti	58	Site Investigator
Daniela Monza	58,163	Site Investigator, Language Coordinator
Lorenzo Nanetti	58	Site Investigator
Marta Panzeri	58	Site Investigator
Dominga Paridi	58	Site Investigator
Paola Soliveri	58	Site Investigator

Name	Location	Contribution/Role
Francesca Spagnolo	58	Site Investigator
Franco Taroni	58	Site Investigator
Chiara Tomasello	58	Site Investigator
Giuseppe De Michele	59	Site Investigator
Luigi Di Maio	59	Site Investigator
Carlo Rinaldi	59	Site Investigator
Marco Massarelli	59	Site Investigator
Silvio Peluso	59	Site Investigator
Alessandro Roca	59	Site Investigator
Cinzia Valeria Russo	59	Site Investigator
Elena Salvatore	59	Site Investigator
Pierpaolo Sorrentino	59	Site Investigator
Tecla Tucci	59	Site Investigator
Milena Cannella	60	Site Investigator
Valentina Codella	60	Site Investigator
Francesca De Gregorio	60	Site Investigator
Annunziata De Nicola	60	Site Investigator
Francesca Elifani	60	Site Investigator
Chiara Esposito	60	Site Investigator
Tiziana Martino	60	Site Investigator
Irene Mazzante	60	Site Investigator
Martina Petrollini	60	Site Investigator
Maria Simonelli	60	Site Investigator
Maurizio Vezza	60	Site Investigator
Ferdinando Squitieri	61	Site Investigator
Barbara D'Alessio	62	Site Investigator
Francesca Lovo	62	Site Investigator
Anna Rita Bentivoglio	63	Site Investigator, REGISTRY Steering Committee
Francesco Bove	63	Site Investigator
Claudio Catalli	63	Site Investigator
Raffaella Di Giacopo	63	Site Investigator
Alfonso Fasano	63	Site Investigator
Marina Frontali	63,64	Site Investigator
Arianna Guidubaldi	63	Site Investigator
Tamara Ialongo	63	Site Investigator
Gioia Jacopini	63,64	Site Investigator
Giovanna Loria	63	Site Investigator

Name	Location	Contribution/Role
Anna Modoni	63	Site Investigator
Martina Petracca	63	Site Investigator
Carla Piano	63	Site Investigator
Piccininni Chiara	63	Site Investigator
Davide Quaranta	63	Site Investigator
Silvia Romano	63,64	Site Investigator
Francesco Soleti	63	Site Investigator
Marcella Solito	63	Site Investigator
Maria Spadaro	63	Site Investigator
Flavia Torlizzi	63	Site Investigator
Paola Zinzi	63,64,163	Site Investigator, Language Coordinator
Giulia Coarelli	64	Site Investigator
Michela Ferraldeschi	64	Site Investigator
Giovanni Ristori	64	Site Investigator
Monique S.E. van Hout	65	Site Investigator
Jeroen P.P. van Vugt	65	Site Investigator
A. Marit de Weert	65	Site Investigator
Marloes Verhoeven	65	Site Investigator
Meike Dekker	66	Site Investigator
Jesper Klooster	66	Site Investigator
Nico Leenders	66	Site Investigator
Joost van Oostrom	66	Site Investigator
Berry Kremer	66,69	Site Investigator
Verena Baake	67	Site Investigator
Simon J. A. van den Bogaard	67	Site Investigator
Reineke Bos	67,163	Site Investigator, Language Coordinator
Eve M. Dumas	67	Site Investigator
Ellen P. ‘t Hart	67	Site Investigator
Marye Hogenboom	67	Site Investigator
Milou Jacobs	67	Site Investigator
Caroline Jurgens	67	Site Investigator
Anne Kampstra	67	Site Investigator
Raymund A.C. Roos	67	Site Investigator, REGISTRY Steering Committee
Anne Schoonderbeek	67	Site Investigator
Marie-Noëlle Witjes-Ané	67	Site Investigator
Annelien Duits	68	Site Investigator
Mayke Oosterloo	68	Site Investigator

Name	Location	Contribution/Role
Mirella Waber	68	Site Investigator
Carla Verstappen	69	Site Investigator
Ellen Økland Blinkenberg	70	Site Investigator
Erik Hauge	71	Site Investigator
Hilde Tyvoll	71	Site Investigator
Olaf Aaserud	72	Site Investigator
Nils Olaf Aanonsen	72	Site Investigator
Kathrine Bjørgo	72	Site Investigator
Nancy Borgerød	72	Site Investigator
Elisabeth Dramstad	72	Site Investigator
Madeleine Fannemel	72	Site Investigator
Jan C. Frich	72	Site Investigator, REGISTRY Steering Committee
Per F. Gørvell	72	Site Investigator
Kathrine Haggag	72	Site Investigator
Cecilie Haggag Johannessen	72	Site Investigator
Arvid Heiberg	72	Site Investigator, REGISTRY Steering Committee
Lars Retterstøl	72	Site Investigator
Oddveig Røsby	72	Site Investigator
Jutta Rummel	72	Site Investigator
Alma Sikiric	72	Site Investigator
Bodil Stokke	72	Site Investigator
Marleen van Walsem	72	Site Investigator
Ragnhild Wehus	72	Site Investigator
Vibeke Arntsen	73	Site Investigator
Inga Bjørnevoll	73	Site Investigator
Sigrid Botne Sando	73	Site Investigator
Marte Gjøl Haug	73	Site Investigator
Hanna Haugan Størseth	73	Site Investigator
Rune Østern	73	Site Investigator
Julie Paulsen	73	Site Investigator
Artur Dziadkiewicz	74	Site Investigator
Agnieszka Konkel	74	Site Investigator
Ewa Narożańska	74	Site Investigator
Malgorzata Nowak	74	Site Investigator
Piotr Robowski	74	Site Investigator
Emilia Sitek	74	Site Investigator
Jaroslaw Slawek	74	Site Investigator

Name	Location	Contribution/Role
Witold Soltan	74	Site Investigator
Michal Szinwelski	74	Site Investigator
Michał Arkuszewski	75	Site Investigator
Magdalena Błaszczyk	75	Site Investigator
Magdalena Boczarska-Jedynak	75	Site Investigator
Ewelina Ciach-Wysocka	75	Site Investigator
Agnieszka Gorzkowska	75	Site Investigator
Barbara Jasińska-Myga	75	Site Investigator
Aleksandra Kaczmarczyk	75	Site Investigator
Gabriela Kłodowska – Duda	75	Site Investigator
Grzegorz Opala	75	Site Investigator
Monika Rudzińska	75,76	Site Investigator
Daniel Stompel	75	Site Investigator
Krzysztof Banaszkiewicz	76	Site Investigator
Dorota Boćwińska	76	Site Investigator
Kamila Bojakowska-Jaremek	76	Site Investigator
Małgorzata Dec	76	Site Investigator
Natalia Grabska	76	Site Investigator
Malgorzata Krawczyk	76	Site Investigator
Ewelina Kubowicz	76	Site Investigator
Michalina Malec-Litwinowicz	76	Site Investigator
Agata Stenwak	76	Site Investigator
Andrzej Szczudlik	76	Site Investigator
Elżbieta Szczygieł	76	Site Investigator
Magdalena Wójcik	76	Site Investigator
Anna Wasielewska	76	Site Investigator
Jacek Anioła Anna Bryl	77	Site Investigator
Anna Ciesielska	77	Site Investigator
Aneta Klimberg	77	Site Investigator
Jerzy Marcinkowski	77	Site Investigator
Husam Samara	77	Site Investigator
Justyna Sempołowicz	77	Site Investigator
Bartłomiej Wiśniewski	77	Site Investigator
Daniel Zielonka	77	Site Investigator
Anna Gogol (formerly Kalbarczyk)	78	Site Investigator
Piotr Janik	78	Site Investigator
Zygmunt Jamrozik	78	Site Investigator

Name	Location	Contribution/Role
Anna Kaminska	78	Site Investigator
Hubert Kwiecinski+	78	Site Investigator
Jakub Antczak	79	Site Investigator
Katarzyna Jachinska	79	Site Investigator
Wioletta Krysa	79	Site Investigator
Maryla Rakowicz	79	Site Investigator
Rafal Rola	79	Site Investigator
Danuta Ryglewicz	79	Site Investigator
Halina Sienkiewicz-Jarosz	79	Site Investigator
Iwona Stępniak	79	Site Investigator
Anna Sułek	79	Site Investigator
Grzegorz Witkowski	79,163	Site Investigator, Language Coordinator
Jacek Zaremba	79	Site Investigator, REGISTRY Steering Committee
Elzbieta Zdzienicka	79	Site Investigator
Karolina Ziora-Jakutowicz	79	Site Investigator
Cristina Januário	80	Site Investigator
Filipa Júlio	80	Site Investigator
Manuel Almeida	81	Site Investigator
Ana Calado	81	Site Investigator
Margarida Dias	81	Site Investigator
Joana Morgado	81	Site Investigator
Cristina Semedo	81	Site Investigator
Leonor Correia Guedes	82,163	Site Investigator, Language Coordinator
Miguel Coelho	82	Site Investigator
Joaquim J Ferreira	82	Site Investigator, REGISTRY Steering Committee
Andreia Magalhães	82	Site Investigator
Tiago Mestre	82,163	Site Investigator, Language Coordinator
Tiago Mendes	82,83	Site Investigator
Dulce Neutel	82	Site Investigator
Filipe Rodrigues	82	Site Investigator
Anabela Valadas	82	Site Investigator
Cristina Costa	83	Site Investigator
Helena Cardoso	83	Site Investigator
Mariana Santos	83	Site Investigator
Gonçalo Cação	84	Site Investigator
Sara Cavaco	84	Site Investigator
Joana Damásio	84	Site Investigator

1

Name	Location	Contribution/Role
Joana Fernandes	84	Site Investigator
Alexandra Gonçalves	84	Site Investigator
Rui Loureiro	84	Site Investigator
Inês Moreira	84	Site Investigator
Marina Magalhães	84	Site Investigator
Paula Salgado	84	Site Investigator
Carlos Andrade	85	Site Investigator
Andreia Costa	85	Site Investigator
Carolina Garrett	85	Site Investigator
Miguel Gago	85	Site Investigator
Joana Guimarães	85	Site Investigator
João Massano	85	Site Investigator
Joana Meireles	85	Site Investigator
Ana Monteiro	85	Site Investigator
Diana Khasanova	86	Site Investigator
Zuleykha Zalyalova	86	Site Investigator
Sergey Illarioshkin	87	Site Investigator, REGISTRY Steering Committee
Sergey Klyushnikov	87	Site Investigator
Olga Sidorova	87	Site Investigator
Oleg Smirnov	87	Site Investigator
Elizaveta Yudina	87,163	Site Investigator, Language Coordinator
Yury Seliverstov	87,163	Site Investigator, Language Coordinator
Victoria Antonova	88	Site Investigator
Svetlana Kopishinskaya	88	Site Investigator
Maria Korotysh	88	Site Investigator
Rim Magzhanov	89	Site Investigator
Elena Saifullina	89	Site Investigator
Sergey Kurbatov	90	Site Investigator
Pilar Solis	91	Site Investigator
Carmen Durán Herrera	92	Site Investigator
Patrocinio Garcia Moreno	92	Site Investigator
Jordi Bas	93	Site Investigator
Núria Busquets	93	Site Investigator
Matilde Calopa	93	Site Investigator
Serge Jaumà Classen	93	Site Investigator
Nadia Rodríguez Dedichá	93	Site Investigator
María Teresa Buongiorno	94	Site Investigator

Name	Location	Contribution/Role
Andrés de la Cerda Santa María	94	Site Investigator
Esteban Muñoz	94	Site Investigator
Pilar Santacruz	94	Site Investigator
Miquel Aguilar Barbera	95	Site Investigator
Ana Rojo Sebastián	95	Site Investigator, REGISTRY Steering Committee
Sonia Arribas Pardo	95	Site Investigator
Dolors Badenes Guia	95	Site Investigator
Noemi Calzado	95	Site Investigator
Laura Casas Hernanz	95	Site Investigator
Juan Pablo Tartari Díaz-Zorita	95	Site Investigator
Judit López Catena	95	Site Investigator
Pilar Quiléz Ferrer	95	Site Investigator
Gemma Tome Carruesco	95	Site Investigator
Misericordia Floriach Robert	96	Site Investigator
Cèlia Mareca Viladrich	96	Site Investigator
Elvira Roca	96	Site Investigator
Jesús Miguel Ruiz Idiago	96	Site Investigator
Antonio Villa Riballo	96	Site Investigator
Antonia Campolongo	97	Site Investigator
Ramon Fernandez de Bobadilla	97	Site Investigator
Andrea Horta	97,163	Site Investigator, Language Coordinator
Jaime Kulisevsky Bojarsky	97	Site Investigator
Saul Martinez-Horta	97,163	Site Investigator, Language Coordinator
Javier Pagonabarraga	97	Site Investigator
Jesus Perez Perez	97	Site Investigator
Roser Ribosa	97	Site Investigator
Carolina Villa	97	Site Investigator
Maria Angeles Acera Gil	98	Site Investigator
Koldo Berganzo Corrales	98	Site Investigator
Juan Carlos Gomez Esteban	98	Site Investigator
Amaia González	98	Site Investigator
Beatriz Tijero Merino	98	Site Investigator
Esther Cubo	99	Site Investigator
Cecilia Gil Polo	99	Site Investigator
Natividad Mariscal	99	Site Investigator
Jesús Sánchez	99	Site Investigator
Sandra Gutierrez Romero	100	Site Investigator

1

Name	Location	Contribution/Role
José Matías Arbelo	100	Site Investigator
Rocío Malo de Molina	100	Site Investigator
Idaira Martín	100	Site Investigator
Juan Manuel Periañez	100	Site Investigator
Beatriz Udaeta	100	Site Investigator
Fernando Alonso-Frech	101	Site Investigator
María del Valle Loarte	101	Site Investigator
Francisco Barrero	102	Site Investigator
Blas Morales	102	Site Investigator
Belén Frades	103	Site Investigator
Marina Ávila Villanueva	103	Site Investigator
Maria Ascension Zea Sevilla	103	Site Investigator
María del Mar Fenollar	104	Site Investigator
Rocío García-Ramos García	104	Site Investigator
Clara Villanueva	104	Site Investigator
Mónica Bascuñana	105	Site Investigator
Marta Fatás Ventura	105	Site Investigator
Juan García Caldentey	105,106,109	Site Investigator
Guillermo García Ribas	105	Site Investigator
Justo García de Yébenes	105	Site Investigator
José Luis López–Sendón Moreno	105	Site Investigator
Verónica Mañanes Barral	105	Site Investigator
Patricia Trigo Cubillo	105,163	Site Investigator, Language Coordinator
Cici Feliz	106	Site Investigator
Pedro José García Ruíz	106	Site Investigator
Ana García	106	Site Investigator
Rosa Guerrero López	106	Site Investigator
Antonio Herranz Bárcenas	106	Site Investigator
Asunción Martínez-Descals	106,163	Site Investigator, Language Coordinator
Angel Martínez Pueyo	106	Site Investigator
Veronica Puertas Martin	106	Site Investigator
Noelia Rodríguez Martínez	106	Site Investigator
Teresa Montojo	106	Site Investigator
María José Sainz Artiga	106	Site Investigator
Vicenta Sánchez	106	Site Investigator
María Dolores Alarcón	107	Site Investigator
Carmen Antúnez Almagro	107	Site Investigator

Name	Location	Contribution/Role
Esther Diéguez	107	Site Investigator
Lorenza Fortuna	107	Site Investigator
Agustina Legaz	107	Site Investigator
Salvadora Manzanares	107	Site Investigator
Juan Marín Muñoz	107	Site Investigator
María Martirio Antequera Torres	107	Site Investigator
Fuensanta Noguera Perea	107	Site Investigator
Laura Vivancos	107	Site Investigator
Sonia González	108	Site Investigator
Luis Menéndez Guisasola	108	Site Investigator
Marta Para Prieto	108	Site Investigator
René Ribacoba	108	Site Investigator
Carlos Salvador	108	Site Investigator
Pablo Sánchez Lozano	108	Site Investigator
Inés Legarda Ramirez	109	Site Investigator
Dolors Moragues Benito	109	Site Investigator
Penelope Navas Arques	109	Site Investigator
Monica Rodriguez Lopera	109	Site Investigator
Barbara Vives Pastor	109	Site Investigator
Itziar Gaston	110	Site Investigator
Fermin Garcia-Amigot	110	Site Investigator
Maria Dolores Martinez-Jaurrieta	110	Site Investigator
Maria Antonia Ramos-Arroyo	110	Site Investigator, REGISTRY Steering Committee
Astrid Adarmes	111	Site Investigator
Maravilla Bernal-Escudero	111	Site Investigator
Fátima Carrillo	111	Site Investigator
Silvia Jesús	111	Site Investigator
Pablo Mir	111	Site Investigator
Laura Vargas-González	111	Site Investigator
Fátima Damas Hermoso	112	Site Investigator
José Manuel García Moreno	112	Site Investigator
Javier Abril Jaramillo	112	Site Investigator
Carolina Mendez Lucena	112	Site Investigator
Eva María Pacheco Cortegana	112	Site Investigator
José Chacón Peña	112	Site Investigator
Luis Redondo	112	Site Investigator
Violeta Sánchez Sánchez	112	Site Investigator

1

Name	Location	Contribution/Role
Cristina Melgar Fernandez	113	Site Investigator
María Dolores Romero Lemos	113	Site Investigator
Maite Paredes Mata	113	Site Investigator
Rocío Villagrán Casado	113	Site Investigator
Maria Bosca	114	Site Investigator
Juan Andres Burguera	114	Site Investigator
Francisco Castera Brugada	114	Site Investigator
Jose Maria Millán Salvador	114	Site Investigator
Carmen Peiró Vilaplana	114	Site Investigator
Pilar Solís	114	Site Investigator
Begoña Jeweinat Figuerola	114	Site Investigator
Paloma Millan Palanca	115	Site Investigator
Elena Bellosta Diago	115	Site Investigator
Javier López del Val	115	Site Investigator
Laura Martinez Martinez	115	Site Investigator
Elena López	115	Site Investigator
Jan Wahlström+	116	Site Investigator, REGISTRY Steering Committee
Ulrika Høsterey-Ugander	116	Site Investigator
Gunnel Fredlund	116	Site Investigator
Radu Constantinescu	116	Site Investigator
Kajsa Lewin	116	Site Investigator
Liselotte Neleborn-Lingefjärd	116	Site Investigator
Maria Berglund	116	Site Investigator
Peter Berglund	116	Site Investigator
Petra Linnsand	116	Site Investigator
Åsa Petersén	117	Site Investigator
Jan Reimer	117	Site Investigator
Håkan Widner	117	Site Investigator
Mouna Esmaeilzadeh	118	Site Investigator
Joakim Tedroff	118	Site Investigator
Elisabeth Winnberg	118	Site Investigator
Stanislav Benaminov	119	Site Investigator
Elisabeth Björnsson	119	Site Investigator
Daniel Merrick	119	Site Investigator
Martin Paucar	119	Site Investigator
Sven Pålhagen	119	Site Investigator, REGISTRY Steering Committee
Per Svenningsson	119	Site Investigator

Name	Location	Contribution/Role
Tina Wallden	119	Site Investigator
Måns Berglund	120	Site Investigator
Ghada Loutfi	120	Site Investigator
Carina Olofsson	120	Site Investigator
Eva-Lena Stattin	120	Site Investigator
Laila Westman	120	Site Investigator
Birgitta Wikström	120	Site Investigator
Camilla Ekwall	121	Site Investigator
Marie-Lousie Göller	121	Site Investigator
Anders Johansson	121	Site Investigator
Valter Niemelä	121	Site Investigator
Dag Nyholm	121	Site Investigator
Leif Wiklund	121	Site Investigator
Jean-Marc Burgunder	122,161	Site Investigator, REGISTRY Steering Committee
Jessica Koehli	122	Site Investigator
Yanik Stebler	122	Site Investigator
Alain Kaelin	123	Site Investigator
Irene Romero	123	Site Investigator
Michael Schüpbach	123	Site Investigator
Sabine Weber Zaugg	123	Site Investigator
Federica Esposito	124	Site Investigator
Jean-Marc Good	124	Site Investigator
Karin Paus	124	Site Investigator
Francois Vingerhoets	124	Site Investigator
Christian Wider+	124	Site Investigator
Hans H. Jung	125	Site Investigator
Jens A. Petersen	125	Site Investigator
Maria Ligon-Auer	125	Site Investigator
Violeta Mihaylova	125	Site Investigator
Lorna Downie	126	Site Investigator
Roisin Jack	126	Site Investigator
Kirsty Matheson	126	Site Investigator
Zosia Miedzybrodzka	126	Site Investigator
Daniela Rae	126	Site Investigator
Sheila A Simpson	126	Site Investigator
Fiona Summers	126	Site Investigator
Alexandra Ure	126	Site Investigator

1

Name	Location	Contribution/Role
Vivien Vaughan	126	Site Investigator
Timothy Harrower	127,135	Site Investigator
Nathan Vernon	127	Site Investigator
Shahbana Akhtar	128	Site Investigator
Jenny Crooks	128	Site Investigator
Adrienne Curtis	128	Site Investigator
Jenny de Souza (Keylock)	128	Site Investigator
John Piedad	128	Site Investigator
Hugh Rickards	128	Site Investigator
Jan Wright	128	Site Investigator
Diane Haig-Brown	129,154	Site Investigator
Janet Craven	129,154	Site Investigator
Andrew Pallett	129	Site Investigator
Steve Simpson	129,154	Site Investigator
Rebecca Weekes	129,154	Site Investigator
Elizabeth Coulthard	130	Site Investigator
Louise Gethin	130	Site Investigator
Beverley Hayward	130	Site Investigator
Kasia Sieradzan	130	Site Investigator
Abigail Wright	130,163	Site Investigator, Language Coordinator
Roger A. Barker	131	Site Investigator
Deidre O'Keefe	131	Site Investigator
Anna Gerrtiz (nee Di Pietro)	131	Site Investigator
Kate Fisher	131	Site Investigator
Anna Goodman	131	Site Investigator
Susan Hill	131	Site Investigator
Sarah Mason	131	Site Investigator
Rachel Swain	131	Site Investigator
Natalie Valle Guzman	131	Site Investigator
Jonathan Bisson	132	Site Investigator
Monica Busse	132	Site Investigator
Cynthia Butcher	132	Site Investigator
Jenny Callaghan	132,149	Site Investigator, Language Coordinator
Rebecca Cousins	132	Site Investigator
Stephen Dunnett	132	Site Investigator, REGISTRY Steering Committee
Catherine Clenaghan	132	Site Investigator
Ruth Fullam	132,149	Site Investigator, Language Coordinator

Name	Location	Contribution/Role
Sarah Hunt	132	Site Investigator
Lesley Jones	132	Site Investigator
Una Jones	132	Site Investigator
Hanan Khalil	132	Site Investigator
Sara Minster	132,163	Site Investigator, Language Coordinator
Michael Owen	132	Site Investigator
Kathleen Price	132	Site Investigator
Jenny Townhill	132,163	Site Investigator, Language Coordinator
Anne Rosser	132	Site Investigator
David Goudie	133	Site Investigator
Lindsay Buchanan	133	Site Investigator
Paula McFadyen	133	Site Investigator
Alison Tonner	133	Site Investigator
Anne-Marie Taylor	133	Site Investigator
Maureen Edwards	134	Site Investigator
Carrie Ho (Scottish Huntington´s Association)	134	Site Investigator
Marie McGill	134	Site Investigator
Mary Porteous	134	Site Investigator
Pauline Pearson	134	Site Investigator
Sarah Irvine	135	Site Investigator
Peter Brockie	136	Site Investigator
Jillian Foster	136	Site Investigator
Nicola Johns	136	Site Investigator
Sue McKenzie	136	Site Investigator
Jean Rothery	136	Site Investigator
Gareth Thomas	136	Site Investigator
Shona Yates	136	Site Investigator
Christian Neumann	137	Site Investigator
Kirsten Patterson	137	Site Investigator
David Thomson	137	Site Investigator
Catherine Deith	138	Site Investigator
Jane Ireland	138	Site Investigator
Stuart Ritchie	138	Site Investigator
Pauline Brown	139	Site Investigator
Liz Burrows	139	Site Investigator
Amy Fletcher	139	Site Investigator
Alison Harding	139	Site Investigator

1

Name	Location	Contribution/Role
Kaye Harrison	139	Site Investigator
Fiona Laver	139	Site Investigator
Mark Silva	139	Site Investigator
Aileen Thomson	139	Site Investigator
Carol Chu	140	Site Investigator
Carole Evans	140	Site Investigator
Deena Gallentree	140	Site Investigator
Stephanie Hamer	140,142	Site Investigator
Alison Kraus	140,142	Site Investigator
Ivana Markova	140,142	Site Investigator
Ashok Raman	140,142	Site Investigator
Liz Rowett	140,142	Site Investigator
Alyson Andrew	141	Site Investigator
Julie Frost	141	Site Investigator
Rupert Noad	141	Site Investigator
Jeremy Cosgrove	142	Site Investigator
Deena Gallantree	142	Site Investigator
Emma Hobson	142	Site Investigator
Stuart Jamieson	142	Site Investigator
Mandy Longthorpe	142	Site Investigator
Hannah Musgrave	142	Site Investigator
Caroline Peacy	142	Site Investigator
Jean Toscano	142	Site Investigator
Sue Wild	142	Site Investigator
Pam Yardumian	142	Site Investigator
Carole Clayton	143	Site Investigator
Heather Dipple	143	Site Investigator
Dawn Freire-Patino	143	Site Investigator
Caroline Hallam	143	Site Investigator
Julia Middleton	143	Site Investigator
Sundus Alusi	144	Site Investigator
Rhys Davies	144	Site Investigator
Kevin Foy	144	Site Investigator
Emily Gerrans	144	Site Investigator
Louise Pate	144	Site Investigator
Uruj Anjum	145	Site Investigator
Jan Coebergh	145	Site Investigator

Name	Location	Contribution/Role
Charlotte Eddy	145	Site Investigator
Nayana Lahiri	145,147	Site Investigator
Meriel McEntagart	145	Site Investigator
Michael Patton	145	Site Investigator
Maria Peterson	145	Site Investigator
Sarah Rose	145	Site Investigator
Thomasin Andrews	146,147	Site Investigator
Andrew Dougherty	146	Site Investigator
Charlotte Golding	146,147	Site Investigator
Fred Kavalier	146	Site Investigator
Hana Laing	146	Site Investigator
Alison Lashwood	146	Site Investigator
Dene Robertson	146	Site Investigator
Deborah Ruddy	146	Site Investigator
Alastair Santhouse	146	Site Investigator
Anna Whaite	146	Site Investigator
Stefanie Gosling (nee Brown)	147	Site Investigator
Stefania Bruno	147	Site Investigator
Elvina Chu	147,151	Site Investigator
Karen Doherty	147	Site Investigator
Salman Haider	147	Site Investigator
Davina Hensman	147	Site Investigator
Monica Lewis	147	Site Investigator
Marianne Novak	147	Site Investigator
Aakta Patel	147	Site Investigator
Nicola Robertson	147	Site Investigator
Elisabeth Rosser	147	Site Investigator
Sarah Tabrizi	147	Site Investigator, REGISTRY Steering Committee
Rachel Taylor	147	Site Investigator
Thomas Warner	147	Site Investigator
Edward Wild	147	Site Investigator
Oda Ackermann	148	Site Investigator
Sophie Duport	148	Site Investigator
Adrienne Scott	148	Site Investigator
Nicholas Stoy	148	Site Investigator
Jenny Vaughn	148	Site Investigator
Natalie Arran	149	Site Investigator

Name	Location	Contribution/Role
Judith Bek	149	Site Investigator
David Craufurd	149	Site Investigator
Marianne Hare	149,155	Site Investigator
Liz Howard	149	Site Investigator
Susan Huson	149	Site Investigator
Liz Johnson	149	Site Investigator
Mary Jones	149	Site Investigator
Ashok Krishnamoorthy	149	Site Investigator
Helen Murphy	149	Site Investigator
Emma Oughton	149	Site Investigator
Lucy Partington-Jones	149	Site Investigator
Dawn Rogers	149,163	Site Investigator, Language Coordinator
Andrea Sollom	149	Site Investigator
Julie Snowden	149	Site Investigator
Cheryl Stopford	149	Site Investigator
Jennifer Thompson	149	Site Investigator
Iris Trender-Gerhard	149	Site Investigator
Nichola Verstraelen (formerly Ritchie)	149	Site Investigator
Leann Westmoreland	149	Site Investigator
Ginette Cass	150	Site Investigator
Lynn Davidson	150	Site Investigator
Jill Davison	150	Site Investigator
Neil Fullerton	150	Site Investigator
Katrina Holmes	150	Site Investigator
Suresh Komati	150	Site Investigator
Sharon McDonnell	150	Site Investigator
Zeid Mohammed	150	Site Investigator
Karen Morgan	150	Site Investigator
Lois Savage	150	Site Investigator
Baldev Singh	150	Site Investigator
Josh Wood	150	Site Investigator
Caroline Knight	151	Site Investigator
Mari O'Neill	151	Site Investigator
Debasish Das Purkayastha	151	Site Investigator
Andrea H Nemeth	152	Site Investigator
Gill Siuda	152	Site Investigator
Ruth Valentine	152	Site Investigator

Name	Location	Contribution/Role
Kathryn Dixon	152,156	Site Investigator
Richard Armstrong	152,156	Site Investigator
David Harrison	153	Site Investigator
Max Hughes	153	Site Investigator
Sandra Large	153	Site Investigator
John O Donovan	153	Site Investigator
Amy Palmer	153	Site Investigator
Andrew Parkinson	153	Site Investigator
Beverley Soltysiak	153	Site Investigator
Leanne Timings	153	Site Investigator
Josh Williams	153	Site Investigator
John Burn	154	Site Investigator
Wendy Bailey	154	Site Investigator
Caroline Coleman	154	Site Investigator
Tahir Majeed	155	Site Investigator
Nicola Verstraelen (Ritchie)	155	Site Investigator
Wendy Barrett	156	Site Investigator
Aileen Ho	156	Site Investigator
Oliver Bandmann	157	Site Investigator
Alyson Bradbury	157	Site Investigator
Helen Fairtlough	157	Site Investigator
Kay Fillingham	157	Site Investigator
Isabella Foustanos	157	Site Investigator
Paul Gill	157	Site Investigator
Mbombe Kazoka	157	Site Investigator
Kirsty O'Donovan	157	Site Investigator
Louise Nevitt	157	Site Investigator
Nadia Peppa	157,163	Site Investigator, Language Coordinator
Oliver Quarrell	157	Site Investigator, REGISTRY Steering Committee
Cat Taylor	157	Site Investigator
Katherine Tidswell	157	Site Investigator
Christopher Kipps	158	Site Investigator
Lesley MacKinnon	158	Site Investigator
Veena Agarwal	158	Site Investigator
Elaine Hayward	158	Site Investigator
Kerry Gunner	158	Site Investigator
Kayla Harris	158	Site Investigator

Name	Location	Contribution/Role
Mary Anderson	158	Site Investigator
Melanie Heywood	158	Site Investigator
Liane Keys	158	Site Investigator
Sarah Smalley	158	Site Investigator
George El-Nimr	159	Site Investigator
Allison Duffell	159	Site Investigator
Sue Wood	159	Site Investigator
Karen Kennedy (nee Smith)	159	Site Investigator
Lesley Gowers	160	Site Investigator
Kingsley Powell	160	Site Investigator
Pamela Bethwaite	160	Site Investigator
Rachel Edwards	160	Site Investigator
Kathleen Fuller	160	Site Investigator
Michelle Phillips	160	Site Investigator
Louis Tan	161	Site Investigator
Puay Ngoh Lau	161	Site Investigator
Emmanuel Pica	161	Site Investigator
Ida Biunno	162	Site Investigator, REGISTRY Steering Committee
Juliana Bronzova	163	Site Investigator, REGISTRY Steering Committee
Joe Giuliano	164	Site Investigator, REGISTRY Steering Committee
Olivia J. Handley	163	Site Investigator, REGISTRY Steering Committee
Torsten Illmann	165	Site Investigator, REGISTRY Steering Committee
Jamie Levey	163	Site Investigator, REGISTRY Steering Committee

Name	Location	Contribution/Role
Tim McLean	163	Site Investigator, REGISTRY Steering Committee
Susana Pro Koivisto	163,167	Site Investigator, REGISTRY Steering Committee, Language Coordinator
Markku Päivärinta	168	Site Investigator, REGISTRY Steering Committee
Tereza Uhrova	169	Site Investigator, REGISTRY Steering Committee
Verena Baake (formerly Rödig)	163	Site Investigator, Language Coordinator
Katrin Barth	163	Site Investigator, Language Coordinator
Monica Bascuñana Garde	163	Site Investigator, Language Coordinator
Kristina Becanovic	163	Site Investigator, Language Coordinator
Tomáš Bernard	163	Site Investigator, Language Coordinator
Sabrina Betz	163	Site Investigator, Language Coordinator
Adrien Come	163	Site Investigator, Language Coordinator
Selene Capodarca	163	Site Investigator, Language Coordinator
Sébastien Charpentier	163	Site Investigator, Language Coordinator
Wildson Vieira da Silva	163	Site Investigator, Language Coordinator
Martina Di Renzo	163	Site Investigator, Language Coordinator
Ana Maria Finisterra	163	Site Investigator, Language Coordinator
Camille Genoves	163	Site Investigator, Language Coordinator
Mette Gilling	163	Site Investigator, Language Coordinator
Olivia J Handley	163	Site Investigator, Language Coordinator
Carina Hvalstedt	163	Site Investigator, Language Coordinator
Hasina Hussain	163	Site Investigator, Language Coordinator
Kerstin Koppers	163	Site Investigator, Language Coordinator
Claudia Lamanna	163	Site Investigator, Language Coordinator

1

Name	Location	Contribution/Role
Matilde Laurà	163	Site Investigator, Language Coordinator
Kristina Münkel	163	Site Investigator, Language Coordinator
Lisanne Mütze	163	Site Investigator, Language Coordinator
Martin Oehmen	163	Site Investigator, Language Coordinator
Helene Padieu	163	Site Investigator, Language Coordinator
Laurent Paterski	163	Site Investigator, Language Coordinator
Beate Rindal	163	Site Investigator, Language Coordinator
Niini Røren (formerly Heinonen)	163	Site Investigator, Language Coordinator
Ana Salgueiro	163	Site Investigator, Language Coordinator
Pavla Šašinková	163	Site Investigator, Language Coordinator
Catherine Taylor	163	Site Investigator, Language Coordinator
Erika Timewell	163	Site Investigator, Language Coordinator
Marleen R van Walsem	163	Site Investigator, Language Coordinator
Marie-Noelle Witjes-Ané	163	Site Investigator, Language Coordinator
Daniel Zielonka	163	Site Investigator, Language Coordinator
Eugeniusz Zielonka	163	Site Investigator, Language Coordinator

Affiliations:

1: Graz (Medizinische Universitäts Graz, Psychiatrie), Austria

2: Innsbruck (Universitätsklinik Innsbruck, Neurologie), Austria

3: Salzburg (Christian-Doppler-Klinik Salzburg, Universitätsklinikum der PMU, Universitätsklinik für Neurologie), Austria

4: Vienna-UNI , Austria

5: Bierbeek, Belgium

6: Bruxelles (Vrije Universiteit Brussel), Belgium

7: Bruxelles (Erasmes) , Belgium

8: Bruxelles (St-Luc), Belgium

9: Charleroi (Institut de Pathologie et de Génétique (IPG)), Belgium

10: Leuven (Universitair Ziekenhuis Gasthuisberg), Belgium

11: Olomouc (Neurologická klinika, Fakultní nemocnice Olomouc), Czech Republic

12: Prague (Extrapyramidové centrum, Neurologická klinika, 1. LF UK a VFN), Czech Republic

13: Aarhus (Aarhus University Hospital), Denmark

14: Copenhagen University Hospital (Rigshospitalet, Memory clinic), Denmark

15: Odense (Odense University Hospital), Denmark

16: Aland, Finland

17: Helsinki - Vaestoliitto (Department of Medical Genetics), Finland

18: Kuopio: Anu Bruun, Finland

19: Oulu (Dep. of Neurology), Finland

20: Oulu (Dep. of Medical Genetics), Finland
21: Tampere (Terveystalo Healthcare Service Centre), Finland
22: Turku-Suvituuli (Rehabilitation Centre Suvituuli), Finland
23: Angers (Centre de référence des maladies neurogénétique- CHU d'Angers), France
24: Bordeaux (Hôpital Pellegrin), France
25: Clermont-Ferrand (Hôpital Gabriel Montpied), France
26: Creteil (Hôpital Henri Mondor), France
27: Lille-Amiens (Lille (CHRU Roger Salengro)) , France
28: Lille-Amiens (Amiens (CHU Sud)) , France
29: Marseille (Hôpital La Timone), France
30: Paris (Hôpital de la Pitié Salpêtrière), France
31: Rouen (Hôpital Charles Nicolle), France
32: Strasbourg (Hôpital Civil), France
33: Toulouse (Hôpital Purpan), France
34: Aachen (Universitätsklinikum Aachen, Neurologische Klinik), Germany
35: Berlin (Universitätsmedizin Berlin, Klinik und Poliklinik für Neurologie), Germany
36: Bochum (Huntington-Zentrum (NRW) Bochum im St. Josef-Hospital), Germany
37: Bremen, Germany
38: Dinslaken (Reha Zentrum in Dinslaken im Gesundheitszentrums Lang), Germany
39: Dresden (Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Klinik und Poliklinik für Neurologie), Germany
40: Erlangen (Universitätsklinikum Erlangen, Molekulare Neurologie und Klinik für Neurologie), Germany
41: Freiburg (Universitätsklinik Freiburg, Neurologie), Germany
42: Hamburg (Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Neurologie), Germany
43: Hannover (Neurologische Klinik mit Klinischer Neurophysiologie, Medizinische Hochschule Hannover), Germany
44: Itzehoe (Schwerpunktpraxis Huntington Neurologie und Psychiatrie), Germany
45: Marburg KPP (Klinik für Psychiatrie und Psychotherapie Marburg-Süd), Germany
46: Marburg UNI (Universitätsklinik Marburg, Sprechstunde für choreatiforme Bewegungsstörungen), Germany
47: München (Huntington-Ambulanz im Neuro-Kopfzentrum - Klinikum rechts der Isar der Neurologischen Klinik und Poliklinik der Technischen Universität München), Germany
48: Münster (Universitätsklinikum Münster, Klinik und Poliklinik für Neurologie), Germany
49: Taufkirchen (Isar-Amper-Klinikum - Klinik Taufkirchen (Vils)), Germany
50: Ulm (Universitätsklinikum Ulm, Neurologie), Germany
51: Würzburg (Universitätsklinikum Würzburg, Neurologie), Germany
52: Bari (Neurophysiopathology of Pain Unit, Basic Medical, Neuroscience and Sensory System Department, University of Bari), Italy

53: Bologna (DIBINEM - Alma Mater Studiorum - Università di Bologna, IRCCS Istituto delle Scienze Neurologiche di Bologna), Italy
54: Brescia (Division of Biology and Genetics, Department of Molecular and Translational Medicine & Division of Neurology, Department of Clinical and Experimental Sciences, University of Brescia), Italy
55: Cagliari (Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari), Italy
56: Florence (Department of NEUROFARBA, University of Florence & Careggi University Hospital, IRCSS " Don Gnocchi "), Italy
57: Genoa (Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova), Italy
58: Milan (SODS Genetica delle Malattie Neurodegenerative e Metaboliche & U.O. Neurologia, Fondazione IRCCS Istituto Neurologico Carlo Besta), Italy
59: Naples (Department of Neurosciences and Reproductive and Odontostomatological Sciences Federico II University of Naples), Italy
60: Pozzilli (IS) (IRCCS Neuromed), Italy
61: IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
62: Rome (LIRH Foundation), Italy
63: Rome (Department of Neurology, Università Cattolica del Sacro Cuore; Institute of Translational Pharmacology & Institute of Cognitive Sciences and Technologies, National Research Council of Italy), Italy
64: Rome (Azienda Ospedaliera Sant'Andrea; Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome; Institute of Translational Pharmacology & Institute of Cognitive Sciences and Technologies, National Research Council of Italy), Italy
65: Enschede (Medisch Spectrum Twente), Netherlands
66: Groningen (Polikliniek Neurologie), Netherlands
67: Leiden (Leiden University Medical Centre (LUMC)), Netherlands
68: Maastricht, Netherlands
69: Nijmegen (Universitair Medisch Centrum St. Radboud, Neurology), Netherlands
70: Bergen (Haukeland University Hospital, Dept of Medical Genetics and Olaviken Psychiatric Hospital), Norway
71: Bergen (NKS Olaviken`s HD clinic), Norway
72: Oslo University Hospital (Dept. of Medical Genetics, Dept. of Neurology, Dept.of Neurorehabilitation), Norway
73: Trondheim (St. Olavs Hospital), Norway
74: Gdansk (St. Adalbert Hospital, Gdansk, Medical University of Gdansk, Neurological and Psychiatric Nursing Dpt.), Poland
75: Katowice (Medical University of Silesia, Katowice), Poland
76: Krakow (Krakowska Akademia Neurologii), Poland
77: Poznan (Poznan University of Medical Sciences), Poland

78: Warsaw-MU (Medical University of Warsaw, Neurology), Poland
79: Warsaw-IPiN (Institute of Psychiatry and Neurology Dep. of Genetics, First Dep. of Neurology), Poland
80: Coimbra – (Hospital Universitário de Coimbra), Portugal
81: Lisbon-Central (Hospital dos Capuchos, Centro Hositalar Lisboa Central), Portugal
82: Lisbon-HSM (Hospital de Santa Maria, Clinical Pharmacology Unit, Instituto de Medicina Molecular), Portugal
83: Lisbon-HFF (Hospital Fernando da Fonseca), Portugal
84: Porto-HGSA (Hospital Santo António- Centro Hospitalar do Porto), Portugal
85: Porto- HSJ (Hospital de São João), Portugal
86: Kazan, Russian Federation
87: Moscow – (Research Center of Neurology) , Russian Federation
88: Nizhny Novgorod – (Nizhny Novgorod Medical Academy, Neurology Department), Russian Federation
89: Ufa – (Bashkir State Medical University, Department of Neurology, Neurosurgery, and Medical Genetics), Russian Federation
90: Voronezh, Russian Federation
91: Alicante-Alcoy (Hospital Virgen de los Lirios), Spain
92: Badajoz (Hospital Infanta Cristina), Spain
93: Barcelona-Bellvitge (Hospital Universitari de Bellvitge), Spain
94: Barcelona- Clínic i Provincial (Hospital Clínic i Provincial), Spain
95: Barcelona-Hospital Mútua de Terrassa, Spain
96: Barcelona-Merced (Hospital Mare de Deu de La Merced), Spain
97: Barcelona-Santa Cruz y San Pablo (Hospital de la Santa Creu i Sant Pau), Spain
98: Bilbao (Hospital de Cruces), Spain
99: Burgos (Servicio de Neurología Hospital General Yagüe), Spain
100: Canarias (Hospital Insular de Gran Canaria), Spain
101: Fuenlabrada (Hospital Universitario), Spain
102: Granada (Hospital Universitario San Cecilio, Neurología), Spain
103: Madrid-BTCIEN (Fundación CIEN), Spain
104: Madrid-Clínico (Hospital Clínico Universitario San Carlos), Spain
105: Madrid RYC (Hospital Ramón y Cajal, Neurología), Spain
106: Madrid FJD (Madrid-Fundación Jiménez Díaz), Spain
107: Murcia (Hospital Universitario Virgen de la Arrixaca), Spain
108: Oviedo (Hospital Central de Asturias), Spain
109: Palma de Mallorca (Hospital Universitario Son Espases), Spain
110: Pamplona (Complejo Hospitalario de Navarra), Spain
111: Sevilla (Hospital Universitario Virgen del Rocío), Spain
112: Sevilla (Hospital Virgen Macarena), Spain
113: Sevilla (Residencia Santa Ana), Spain

114: Valencia (Hospital la Fe), Spain
115: Zaragoza (Hospital Clínico), Spain
116: Göteborg (Sahlgrenska University Hospital), Sweden
117: Lund (Dept Neurology, Skånes Universityhospital), Sweden
118: Stockholm-Ersta, Sweden
119: Stockholm Karolinska University Hospital, Sweden
120: Umeå (Umeå University Hospital), Sweden
121: Uppsala University Hospital, Sweden
122: Bern (Swiss HD Zentrum), Switzerland
123: Bern (Zentrum für Bewegungsstörungen, Neurologische Klinik und Poliklinik, Universität Bern), Switzerland
124: Lausanne, Switzerland
125: Zürich (University Hospital and University of Zurich), Switzerland
126: Aberdeen (NHS Grampian Clinical Genetics Centre & University of Aberdeen), UK
127: Barnstaple, UK
128: Birmingham (The Barberry Centre, Dept of Psychiatry), UK
129: Blanford Forum, UK
130: Bristol (North Bristol NHs Trust, Southmead hospital), UK
131: Cambridge (Cambridge Centre for Brain Repair, Forvie Site), UK
132: Cardiff (Schools of Medicine and Biosciences, Cardiff University), UK
133: Dundee (Scottish Huntington's Association, Ninewells Hospital), UK
134: Edinburgh (SE Scotland Genetic Service, Western General Hospital), UK
135: Exeter (Department of Neurology Royal Devon and Exeter Foundation Trust Hospital), UK
136: Fife (Scottish Huntington's Association Whyteman's Brae Hospital), UK
137: Forth Valley (Neurology Department, Forth Valley Royal Hospital), UK
138: Glasgow (Glasgow HD Management Clinic, Southern General Hospital), UK
139: Gloucester (Department of Neurology Gloucestershire Royal Hospital), UK
140: Hull (Castle Hill Hospital), UK
141: Launceston (Millaton Court), UK
142: Leeds (Chapel Allerton Hospital, Department of Clinical Genetics), UK
143: Leicester (Leicestershire Partnership Trust, Mill Lodge), UK
144: Liverpool (Walton Centre for Neurology and Neurosurgery), UK
145: London (St. Georges-Hospital), UK
146: London (Guy's Hospital), UK
147: London (The National Hospital for Neurology and Neurosurgery), UK
148: London (Royal Hospital for Neuro-disability), UK
149: Manchester (Genetic Medicine, University of Manchester, Manchester Academic Health Sciences Centre and Central Manchester University Hospitals NHS Foundation Trust), UK
150: Newcastle-upon-Tyne (Centre for Life, Institute of Medical Genetics), UK
151: Northampton (St Andrew’s Healthcare), UK

152: Oxford (Oxford University Hospitals NHS Trust, Dept. of Neurosciences, University of Oxford), UK
153: Plymouth (Plymouth Huntington Disease Service, Mount Gould Hospital), UK
154: Poole (Brain Injury Service, Poole Hospital), UK
155: Preston (Neurology Department, Preston Royal Hospital), UK
156: Reading (Royal Berkshire Hospital), UK
157: Sheffield (The Royal Hallamshire Hospital– Sheffield Children's Hospital), UK
158: Southampton (Southampton General Hospital), UK
159: Stoke on Trent (Bucknall Hospital), UK
160: Swindon (Victoria Centre, Great Western Hospital), UK
161: EHDN's associate site in Singapore: National Neuroscience Institute Singapore,
162: Institute for Genetic and Biomedical Research, University of Milan, Italy
163: European Huntington's Disease Network (EHDN), Ulm, Germany,
164: CHDI Foundation, Inc., New York, USA
165: 2mt Software GmbH, Ulm, Germany
166: Clinic of Neurology, Charles University and General Teaching Hospital, Prague, Czech Republic, Czech Republic
167: Center for Rare Disorders, Oslo University Hospital HF, Rikshospitalet, Norway
168: Department of Neurology, Turku University Hospital, Turku, Finland
169: Clinic of Psychiatry, Charles University and General Teaching Hospital, Prague, Czech Republic

Appendix 3 – Huntington's disease clinical characteristics questionnaire (HD-CCQ) questions

Symptom	Question
Motor	Have motor symptoms compatible with HD ever been a part of the subject's medical history? At what age did the subject's motor symptoms begin?
Cognitive	Has significant cognitive impairment (severe enough to impact on work or activities of daily living) or dementia ever been a part of the subject's medical history? At what age did cognitive impairment first start to have an impact on daily life?
Apathy	Has apathy ever been a part of the subject's medical history? At what age did apathy begin?
Depression	Has depression (includes treatment with antidepressants with or without a formally-stated diagnosis of depression) ever been a part of the subject's medical history? At what age did the depression begin?
Perseverative/ obsessive behaviours (POB)	Has perseverative/obsessive behaviours ever been a part of the subject's medical history? At what age did perseverative/obsessive behaviour begin?
Irritability	Has irritability ever been a part of the subject's medical history? At what age did the irritability begin?
Violent or aggressive behaviour (VAB)	Has violent or aggressive behaviour ever been a part of the subject's medical history? At what age did violent or aggressive behaviour begin?
Psychosis	Has psychosis (hallucinations or delusions) ever been a part of the subject's medical history? At what age did psychosis (hallucinations or delusions) begin?

Questionnaire taken from the European Huntington's Disease Network's (EHDN) data dictionary for Registry (Version 3).

References

1 The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. *Cell* 1993; **72**: 971–83.

2 Andrew SE, Paul Goldberg Y, Kremer B, *et al.* The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. *Nat Genet* 1993; **4**: 398–403.

3 Duyao M, Ambrose C, Myers R, *et al.* Trinucleotide repeat length instability and age of onset in Huntington's disease. *Nat Genet* 1993; **4**: 387–92.

4 Bates GP, Dorsey R, Gusella JF, *et al.* Huntington disease. *Nat Rev Dis Prim* 2015; **1**: 15005.

5 Craufurd D, Snowden J. Neuropsychiatry and Neuropsychology. In: Bates GP, Tabrizi SJ, Jones L, eds. Huntington's Disease, 4th edn. New York: Oxford University Press, 2014: 36–65.

6 Scahill RI, Zeun P, Osborne-Crowley K, *et al.* Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. *Lancet Neurol* 2020; **19**: 502–12.

7 Paulsen JS, Long JD, Johnson HJ, *et al.* Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study. *Front Aging Neurosci* 2014; **6**: 78.

8 Tabrizi SJ, Scahill RI, Owen G, *et al.* Predictors of phenotypic progression and

disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. *Lancet Neurol* 2013; **12**: 637–49.

9 Orth M, Handley OJ, Schwenke C, *et al.* Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. *PLoS Curr* 2010; **2**: RRN1184.

10 Eddy CM, Parkinson EG, Rickards HE. Changes in mental state and behaviour in Huntington's disease. *The Lancet Psychiatry* 2016; **3**: 1079–86.

11 Unified Huntington's disease rating scale: Reliability and consistency. *Mov Disord* 1996; **11**: 136–42.

12 Fisher R. On the 'Probable Error' of a Coefficient of Correlation Deduced from a Small Sample. *Metron* 1921; **1**: 3–32.

13 GeM-HD Consortium. Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. *Cell* 2015; **162**: 516–26.

14 Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium. CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset. *Cell* 2019; **178**: 887–900.

15 Landwehrmeyer GB, Fitzer-Attas CJ, Giuliano JD, *et al.* Data Analytics from Enroll-HD, a Global Clinical Research Platform for Huntington's Disease. *Mov Disord Clin Pract* 2017; **4**: 212–24.

16 Dorsey ER. Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study. *PLoS One* 2012; **7**: e29522.

17 Lee J-M, Ramos EM, Lee J-H, *et al.* CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. *Neurology* 2012; **78**: 690–5.

18 Rinaldi C, Salvatore E, Giordano I, *et al.* Predictors of survival in a Huntington's disease population from southern Italy. *Can J Neurol Sci* 2012; **39**: 48–51.

19 Snell R, MacMillan J, Cheadle J, *et al.* Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. *Nat Genet* 1993; **4**: 393–7.

20 Illarioshkin SN, Igarashi S, Onodera O, *et al.* Trinucleotide repeat length and rate of progression of Huntington's disease. *Ann Neurol* 1994; **36**: 630–5.

21 Kieburtz K, MacDonald M, Shih C, *et al.* Trinucleotide repeat length and progression of illness in Huntington's disease. *J Med Genet* 1994; **31**: 872–4.

22 Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. *Clin Genet* 2004; **65**: 267–77.

23 Wexler NS, Lorimer J, Porter J, *et al.* Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. *Proc Natl Acad Sci U S A* 2004; **101**: 3498–503.

24 Oosterloo M, Bijlsma EK, van Kuijk SM, *et al.* Clinical and genetic characteristics of late-onset Huntington's disease. *Park Relat Disord* 2019; **61**: 101–5.

25 Fusilli C, Migliore S, Mazza T, *et al.* Biological and clinical manifestations of

juvenile Huntington's disease: a retrospective analysis. *Lancet Neurol* 2018; **17**: 986–93.

26 Cronin T, Rosser A, Massey T. Clinical Presentation and Features of Juvenile-Onset Huntington's Disease: A Systematic Review. *J Huntingtons Dis* 2019; **8**: 171–9.

27 Hensman Moss DJ, Pardiñas AF, Langbehn D, *et al.* Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. *Lancet Neurol* 2017; **16**: 701–11.

28 Huntington's GM of, Disease Consortium (GeM-HD). Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. *Cell* 2015; **162**: 516–26.

29 Ellis N, Tee A, McAllister B, *et al.* Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntington's Disease. *Biol Psychiatry* 2019; published online Dec 17. DOI:10.1016/j.biopsych.2019.12.010.

30 Andrews SC, Langbehn DR, Craufurd D, *et al.* Apathy predicts rate of cognitive decline over 24 months in premanifest Huntington's disease. *Psychol Med* 2020; : 1–7.

31 Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. *Neuropsychology* 1998; **12**: 426–45.

32 Oosterloo M, Craufurd D, Nijsten H, van Duijn E. Obsessive-Compulsive and Perseverative Behaviors in Huntington's Disease. *J Huntingtons Dis* 2019; **8**: 1–7.

33 Martinez-Horta S, Perez-Perez J, van Duijn E, *et al.* Neuropsychiatric

symptoms are very common in premanifest and early stage Huntington's Disease. *Parkinsonism Relat Disord* 2016; **25**: 58–64.

34 Andrews SC, Craufurd D, Durr A, *et al.* Executive impairment is associated with unawareness of neuropsychiatric symptoms in premanifest and early Huntington's disease. *Neuropsychology* 2018; **32**: 958–65.

35 Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005; **62**: 593–602.

36 Cazeneuve C, Durr A. Genetic and Molecular Studies. In: Bates GP, Tabrizi SJ, Jones L, eds. Huntington's Disease, 4th Editio. New York: Oxford University Press (OUP), 2014: 109–30.

37 Zappacosta B, Monza D, Meoni C, *et al.* Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's disease. *Arch Neurol* 1996; **53**: 493–7.

38 Weigell-Weber M, Schmid W, Spiegel R. Psychiatric symptoms and CAG expansion in Huntington's disease. *Am J Med Genet* 1996; **67**: 53–7.

39 Berrios GE, Wagle AC, Markova IS, *et al.* Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington's disease gene carriers. *Psychiatry Res* 2001; **102**: 217–25.

40 Vassos E, Panas M, Kladi A, Vassilopoulos D. Effect of CAG repeat length on psychiatric disorders in Huntington's disease. *J Psychiatr Res* 2008; **42**: 544–9.

41 Wright GEB, Collins JA, Kay C, *et al.* Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease. *Am J Hum Genet* 2019; **104**: 1116–26.

42 Ciosi M, Maxwell A, Cumming SA, *et al.* A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. *EBioMedicine* 2019; **48**: 568–80.

43 Escott-Price V, Bracher-Smith M, Menzies G, *et al.* Genetic liability to schizophrenia is negatively associated with educational attainment in UK Biobank. *Mol Psychiatry* 2019; published online Jan. DOI:10.1038/s41380-018-0328-6.

44 Orth M, Bronzova J, Tritsch C, Ray Dorsey E, Ferreira JJ, Gemperli A. Comparison of Huntington's Disease in Europe and North America. *Mov Disord Clin Pract* 2017; **4**: 358–67.

45 Tabrizi SJ, Scahill RI, Owen G, *et al.* Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. *Lancet Neurol* 2013; **12**: 637–49.

46 Bachoud-Lévi A-C, Ferreira J, Massart R, *et al.* International Guidelines for the Treatment of Huntington's Disease. *Front Neurol* 2019; **10**: 710.

47 Shahn Z, Li Y, Sun Z, Mohan A, Sampaio C, Hu J. G-Computation and Hierarchical Models for Estimating Multiple Causal Effects From Observational Disease Registries With Irregular Visits. *AMIA Jt Summits Transl Sci*

proceedings AMIA Jt Summits Transl Sci 2019; **2019**: 789–98.

48 Sun Z, Li Y, Ghosh S, *et al.* A Data-Driven Method for Generating Robust Symptom Onset Indicators in Huntington's Disease Registry Data. *AMIA . Annu Symp proceedings AMIA Symp* 2017; **2017**: 1635–44.

49 Long JD, Mills JA. Joint modeling of multivariate longitudinal data and survival data in several observational studies of Huntington's disease. *BMC Med Res Methodol* 2018; **18**: 138.

Tables

	TDS (N=2403)		TIS (N=2403)		SDMT (N=3137)		Stroop Interference (N=3273)	
	Effect (95% CI)	*P*	Effect (95% CI)	*P*	Effect (95% CI)	*P*	Effect (95% CI)	*P*
Motor	0.15 (±1.85)	8.71×10^{-1}	0.67 (±1.93)	4.93×10^{-1}	-12.37 (±3.90)	**5.62×10^{-10}**	-9.34 (±3.76)	**1.19×10^{-6}**
Cognitive	0.38 (±0.39)	5.28×10^{-2}	-0.41 (±0.40)	*4.53×10^{-2}*	-3.52 (±0.81)	**2.28×10^{-17}**	-3.41 (±0.76)	**3.29×10^{-18}**
Apathy	1.73 (±0.40)	**4.05×10^{-17}**	0.48 (±0.42)	*2.36×10^{-2}*	-2.70 (±0.83)	**2.37×10^{-10}**	-2.15 (±0.79)	**1.00×10^{-7}**
Depression	1.49 (±0.40)	**5.67×10^{-13}**	1.13 (±0.42)	**1.37×10^{-7}**	-0.09 (±0.84)	8.41×10^{-1}	-0.53 (±0.79)	1.88×10^{-1}
POB	-0.15 (±0.42)	4.96×10^{-1}	0.04 (±0.44)	8.70×10^{-1}	-1.28 (±0.85)	*3.26×10^{-3}*	-1.10 (±0.80)	*7.45×10^{-3}*
Irritability	0.15 (±0.43)	4.97×10^{-1}	1.82 (±0.45)	**1.99×10^{-15}**	1.28 (±0.89)	*4.52×10^{-3}*	1.01 (±0.84)	*1.76×10^{-2}*
VAB	0.72 (±0.47)	*2.65×10^{-3}*	1.57 (±0.49)	**3.29×10^{-10}**	-1.24 (±0.97)	*1.26×10^{-2}*	-1.20 (±0.92)	*1.06×10^{-2}*
Psychosis	-0.45 (±0.68)	1.98×10^{-1}	-0.50 (±0.71)	1.67×10^{-1}	-2.53 (±1.38)	**3.38×10^{-4}**	-3.18 (±1.28)	**1.07×10^{-6}**
Age	0.01 (±0.02)	2.18×10^{-1}	-0.09 (±0.02)	**8.17×10^{-13}**	-0.53 (±0.05)	**1.02×10^{-99}**	-0.52 (±0.05)	**2.89×10^{-104}**
CAG	-0.03 (±0.06)	3.54×10^{-1}	-0.21 (±0.07)	**1.17×10^{-9}**	-1.56 (±0.14)	**3.97×10^{-102}**	-1.25 (±0.13)	**2.38×10^{-71}**
Sex (F)	-0.12 (±0.37)	5.17×10^{-1}	0.35 (±0.38)	7.14×10^{-2}	-1.28 (±0.76)	**9.73×10^{-4}**	-1.22 (±0.72)	**9.13×10^{-4}**
Duration	0.05 (±0.04)	*5.62×10^{-3}*	0.02 (±0.04)	3.08×10^{-1}	-0.41 (±0.08)	**4.78×10^{-25}**	-0.32 (±0.07)	**4.82×10^{-18}**

Table 1. Association of validated clinical scores with the HD Clinical Characteristics Questionnaire symptoms (shown in italics), and other covariates. For binary covariates (CCQ symptoms and sex) “effect” is the increase/decrease in the clinical score associated with presence of that covariate. For quantitative covariates (age, CAG, duration), “effect” is the change in clinical score associated with an increase of one unit in the covariate. In addition to having a confirmed onset and pathogenic CAG length (36-93), individuals must have no co-morbid diagnosis of schizophrenia, schizotypy or schizoaffective disorder. Significant associations after Bonferroni correction for 4 phenotypes and 12 covariates are shown in bold ($P < 1.04 \times 10^{-3}$) and nominally significant P values are italicised ($P < 0.05$). CI: confidence interval; TDS: Total depression score from the Hospital Anxiety and Depression Scale; TIS: Total irritability score from Snaith’s irritability scale; SDMT: Symbol digits modalities test; POB: perseverative/obsessive behaviour; VAB: violent or aggressive behaviour; Sex (F): female.

	Males			Females				
	Yes	No	Frequency	Yes	No	Frequency	OR (95% CI)	*P* value (c^2)
Motor	2691	28	98.97%	2859	25	99.13%	1.19 (0.69 - 2.05)	5.29×10^{-1}
Cognitive	1584	1132	58.32%	1688	1187	58.71%	1.02 (0.91 - 1.13)	7.66×10^{-1}
Apathy	1456	1259	53.63%	1495	1374	52.11%	0.94 (0.85 - 1.05)	2.56×10^{-1}
Depression	1582	1135	58.23%	2025	853	70.36%	1.70 (1.52 - 1.90)	**2.57×10^{-21}**
POB	1005	1711	37.00%	1038	1834	36.14%	0.96 (0.86 - 1.07)	5.04×10^{-1}
Irritability	1706	1006	62.91%	1634	1240	56.85%	0.78 (0.70 - 0.87)	**4.03×10^{-6}**
VAB	947	1769	34.87%	777	2100	27.01%	0.69 (0.62 - 0.77)	**1.99×10^{-10}**
Psychosis	319	2396	11.75%	325	2549	11.31%	0.96 (0.81 - 1.13)	6.06×10^{-1}

Table 2. Lifetime prevalence of motor and psychiatric symptoms in males and females with HD. Data from HD Clinical Characteristics Questionnaire at last recorded clinic visit in Registry. Chi-square (c^2) tests the difference between prevalence in males and females. Odds ratios (OR) >1 indicates the symptom is more common in females; odds ratios <1 indicates the symptom is more common in males. To be included, individuals must have a pathogenic CAG length (36-93) and confirmed clinical HD onset. Significant *P* values in bold ($P < 6.25 \times 10^{-3}$, multiple testing correction). CI: confidence interval; POB: perseverative/obsessive behaviour; VAB: violent or aggressive behaviour.

	Male		Female		*P*	Both	
	R^2 (95% CI)	N	R^2 (95% CI)	N		R^2 (95% CI)	N
Motor	0.678 (0.657 - 0.697)	2684	0.649 (0.628 - 0.670)	2844	5.42×10^{-2}	0.663 (0.648 - 0.677)	5528
Cognitive	0.610 (0.579 - 0.639)	1570	0.629 (0.600 - 0.656)	1681	3.80×10^{-1}	0.619 (0.598 - 0.639)	3251
Apathy	0.595 (0.562 - 0.627)	1423	0.562 (0.528 - 0.595)	1462	1.83×10^{-1}	0.578 (0.554 - 0.601)	2885
Depression	0.412 (0.374 - 0.449)	1551	0.351 (0.318 - 0.385)	1994	*3.50×10^{-2}*	0.375 (0.350 - 0.400)	3545
POB	0.539 (0.496 - 0.581)	973	0.440 (0.394 - 0.485)	1016	**3.67×10^{-3}**	0.489 (0.457 - 0.52)	1989
Irritability	0.463 (0.428 - 0.498)	1670	0.547 (0.513 - 0.579)	1601	**1.25×10^{-3}**	0.503 (0.478 - 0.527)	3271
VAB	0.479 (0.431 - 0.524)	927	0.478 (0.426 - 0.528)	761	9.79×10^{-1}	0.477 (0.442 - 0.511)	1688
Psychosis	0.401 (0.316 - 0.484)	312	0.424 (0.340 - 0.504)	318	7.29×10^{-1}	0.411 (0.351 - 0.469)	630

Table 3. Variance in age at onset (R^2) explained by pathogenic CAG repeat length for eight symptoms in males and females with HD. Ages at onset were logarithmically transformed and plotted against CAG length. *P* values test difference between male and female R^2. Significant *P* values ($P < 6.25 \times 10^{-3}$; multiple testing correction) are in bold and nominally significant *P* values ($P < 0.05$) italicised. Individuals had to have a clinical onset of HD, a known sex and a pathogenic CAG length (36-93) to be included. CI: confidence interval; POB: perseverative/obsessive behaviour; VAB: violent or aggressive behaviour.

	Motor (N=1644)		Cognitive (N=1644)		Apathy (N=1643)	
	OR (95% CI)	*P*	OR (95% CI)	*P*	OR (95% CI)	*P*
Sex (F)	0.49 (0.14 - 1.66)	2.51×10^{-1}	1.20 (0.97 - 1.49)	9.75×10^{-2}	1.07 (0.87 - 1.31)	5.13×10^{-1}
CAG	0.95 (0.83 - 1.10)	5.10×10^{-1}	1.01 (0.98 - 1.03)	6.64×10^{-1}	0.99 (0.96 - 1.01)	2.32×10^{-1}
Duration	0.91 (0.82 - 1.01)	8.32×10^{-2}	1.00 (0.98 - 1.03)	6.99×10^{-1}	1.00 (0.98 - 1.02)	8.96×10^{-1}
Alcohol	1.00 (0.93 - 1.08)	9.61×10^{-1}	1.02 (1.01 - 1.04)	*8.78×10^{-3}*	1.00 (0.99 - 1.02)	5.56×10^{-1}
Tobacco	1.10 (0.96 - 1.26)	1.54×10^{-1}	1.01 (0.99 - 1.02)	3.00×10^{-1}	1.02 (1.00 - 1.03)	*4.94×10^{-3}*
Education	0.89 (0.75 - 1.06)	1.97×10^{-1}	1.01 (0.98 - 1.05)	4.03×10^{-1}	0.98 (0.95 - 1.01)	2.02×10^{-1}
TFC	1.05 (0.75 - 1.46)	7.85×10^{-1}	0.78 (0.74 - 0.81)	**1.58×10^{-25}**	0.87 (0.84 - 0.91)	**1.14×10^{-9}**
TMS	1.17 (1.08 - 1.27)	**7.81×10^{-5}**	1.00 (0.99 - 1.00)	2.67×10^{-1}	1.00 (0.99 - 1.00)	2.59×10^{-1}

	Depression (N=1645)		POB (N=1641)		Irritability (N=1645)	
	OR (95% CI)	*P*	OR (95% CI)	*P*	OR (95% CI)	*P*
Sex (F)	1.77 (1.44 - 2.17)	**6.98×10^{-8}**	1.07 (0.86 - 1.32)	5.68×10^{-1}	0.75 (0.61 - 0.92)	*5.36×10^{-3}*
CAG	0.96 (0.93 - 0.98)	**1.32×10^{-4}**	1.00 (0.97 - 1.02)	6.93×10^{-1}	0.99 (0.97 - 1.01)	4.74×10^{-1}
Duration	1.03 (1.01 - 1.05)	*1.10×10^{-2}*	1.03 (1.00 - 1.05)	*1.68×10^{-2}*	1.03 (1.01 - 1.05)	*6.84×10^{-3}*
Alcohol	0.99 (0.98 - 1.01)	2.66×10^{-1}	1.00 (0.99 - 1.02)	5.14×10^{-1}	1.01 (0.99 - 1.02)	4.79×10^{-1}
Tobacco	1.02 (1.01 - 1.03)	*8.14×10^{-4}*	1.01 (1.00 - 1.02)	2.04×10^{-1}	1.02 (1.01 - 1.03)	**1.02×10^{-4}**
Education	0.99 (0.96 - 1.02)	5.83×10^{-1}	1.00 (0.97 - 1.03)	8.21×10^{-1}	1.00 (0.97 - 1.03)	8.44×10^{-1}
TFC	0.90 (0.86 - 0.94)	**7.30×10^{-6}**	0.89 (0.85 - 0.93)	**1.10×10^{-6}**	0.93 (0.89 - 0.97)	*8.83×10^{-4}*
TMS	0.98 (0.98 - 0.99)	**2.59×10^{-5}**	0.99 (0.99 - 1.00)	6.09×10^{-2}	0.99 (0.98 - 1.00)	*7.46×10^{-3}*

	VAB (N=1645)		Psychosis (N=1642)	
	OR (95% CI)	*P*	OR (95% CI)	*P*
Sex (F)	0.75 (0.60 - 0.94)	*1.27×10^{-2}*	0.81 (0.57 - 1.14)	2.23×10^{-1}
CAG	1.00 (0.98 - 1.02)	9.42×10^{-1}	0.99 (0.95 - 1.02)	4.84×10^{-1}
Duration	1.04 (1.02 - 1.06)	*9.10×10^{-4}*	1.02 (0.98 - 1.05)	3.47×10^{-1}
Alcohol	1.00 (0.99 - 1.01)	9.29×10^{-1}	1.02 (1.00 - 1.04)	*3.35×10^{-2}*
Tobacco	1.02 (1.01 - 1.03)	*2.08×10^{-3}*	1.00 (0.98 - 1.02)	8.38×10^{-1}
Education	0.99 (0.95 - 1.02)	3.69×10^{-1}	0.92 (0.88 - 0.97)	*2.24×10^{-3}*
TFC	0.88 (0.84 - 0.93)	**2.07×10^{-7}**	0.83 (0.77 - 0.89)	**3.33×10^{-7}**
TMS	0.99 (0.99 - 1.00)	7.49×10^{-2}	0.99 (0.98 - 1.00)	1.47×10^{-1}

Table 4. Psychiatric and cognitive symptoms are associated with reduced functional capacity. Multiple logistic regression using binary HD-CCQ data for 8 symptoms (0 = no symptom; 1 = reported symptom) and clinical covariates. Significant associations after Bonferroni correction for 8 symptoms and 8 covariates are shown in bold ($P < 7.81 \times 10^{-4}$) and nominally significant associations in italics ($P < 0.05$). With the exception of sex, the odds ratio (OR) indicates the effect on the outcome probability associated with an increase of one unit in the covariate. In addition to having a confirmed onset and pathogenic CAG length (36-93), individuals must have no co-morbid diagnosis of schizophrenia, schizotypy or schizoaffective disorder. CI: confidence interval; Sex (F): female; POB: perseverative/obsessive behaviour; TFC: total functional capacity; TMS: total motor score; VAB: violent or aggressive behaviour.


Percentage called
0
20
40
60
Motor
Cognitive
Psychiatric
Oculomotor
Other
Mixed
Onset type
Age group
<20
20-40
40-60
>60


Percentage called
0
10
20
30
40
50
Motor
Cognitive
Psychiatric
Oculomotor
Other
Mixed
Onset type
CAG group
36-39
40-44
45-49
50-54
55-59
>60

Figure 1. The initial manifestation of HD varies with age and CAG length. All included individuals had a pathogenic CAG length (36-93) and confirmed HD onset age determined by a rating clinician. **(A)** Frequency of different onset types in four age groups, chosen to show juvenile HD and then 20 year bins for clarity. Total N=6289; <20 years, N=188; 20-40 years, N=2216; 40-60 years, N=3276; >60 years, N=609. **(B)** Frequency of different onset types in six CAG length groups, chosen for clarity across the pathogenic range. Total N=6289; 36-39 CAG, N=156; 40-44 CAG, N=3813; 45-49 CAG, N=1735; 50-54 CAG, N=387; 55-59 CAG, N=97; >60 CAG, N=101.



Figure 2. The onsets of cognitive and psychiatric symptoms relative to motor onset in HD.

The age at onset of motor symptoms was subtracted from the age at onset of each cognitive/psychiatric symptom when present. Timings of up to +/- 40 years relative to motor onset shown. Only individuals with a rater-confirmed age at onset and CAG length (36-93) were included. Data from HD-CCQ. (**A**) Cognitive impairment N=3225; (**B**) Apathy N=2852; (**C**) Depression N=3495; (**D**) Irritability N=3235.



Figure 3. Mean ages at onset for motor and psychiatric symptoms at different CAG repeat lengths.

Shown are the mean ages at symptom onset as recorded by the HD Clinical Characteristics Questionnaire for apathy (N = 2739), cognitive impairment (N = 3069), depression (N = 3399), irritability (N = 3117) and motor symptoms (N = 4889).

A		Onset type					
	Total N	Motor	Cognitive	Psychiatric	Oculomotor	Other	Mixed
All	6289	50.66%	8.17%	22.42%	0.22%	1.10%	17.43%

B		Onset type					
	Total N	Motor	Cognitive	Psychiatric	Oculomotor	Other	Mixed
<20	188	24.47%	21.81%	28.19%	0.53%	3.19%	21.81%
20-40	2216	46.12%	8.12%	26.17%	0.23%	0.99%	18.37%
40-60	3276	51.89%	7.69%	21.58%	0.24%	1.19%	17.40%
>60	609	68.64%	6.73%	11.49%	0.00%	0.33%	12.81%

C		Onset type					
	Total N	Motor	Cognitive	Psychiatric	Oculomotor	Other	Mixed
36-39	156	50.64%	10.90%	20.51%	0.00%	0.64%	17.31%
40-44	3813	51.25%	7.92%	23.29%	0.21%	1.08%	16.26%
45-49	1735	50.26%	7.44%	22.13%	0.23%	1.27%	18.67%
50-54	387	52.20%	8.53%	18.86%	0.26%	0.26%	19.90%
55-59	97	48.45%	12.37%	17.53%	0.00%	0.00%	21.65%
>60	101	31.68%	20.79%	15.84%	0.99%	3.96%	26.73%

Table e-1. The initial manifestation of HD varies by age and CAG length. All included individuals had a pathogenic CAG length (36-93) and confirmed HD onset age determined by a rating clinician. **(A)** Percentage of different onset types in all individuals. **(B)** Percentage of different onset types observed in four age groups. **(C)** Percentage of different onset types observed across six CAG groups. These data are plotted in Fig. 1A-B.

A	Motor		Cognitive		Psychiatric	
	OR (95% CI)	*P*	OR (95% CI)	*P*	OR (95% CI)	*P*
Age at onset	1.06 (1.04-1.07)	**7.44×10^{-22}**	0.99 (0.99-1.00)	*3.59×10^{-2}*	0.96 (0.95-0.97)	**9.41×10^{-16}**

	Oculomotor		Other		Mixed	
	OR (95% CI)	*P*	OR (95% CI)	*P*	OR (95% CI)	*P*
Age at onset	1.00 (1.00-1.00)	6.06×10^{-1}	1.00 (1.00-1.00)	6.55×10^{-1}	0.99 (0.98-1.00)	*2.94×10^{-2}*

B	Motor		Cognitive		Psychiatric	
	OR (95% CI)	*P*	OR (95% CI)	*P*	OR (95% CI)	*P*
CAG	1.00 (0.96-1.04)	9.67×10^{-1}	1.00 (0.98-1.02)	8.05×10^{-1}	0.96 (0.93-0.99)	*1.97×10^{-2}*

	Oculomotor		Other		Mixed	
	OR (95% CI)	*P*	OR (95% CI)	*P*	OR (95% CI)	*P*
CAG	1.00 (1.00-1.00)	7.93×10^{-1}	1.00 (0.99-1.01)	6.07×10^{-1}	1.01 (0.99-1.04)	*9.98×10^{-3}*

Table e-2. Age at onset, but not CAG length, is associated with initial manifestation type in adult-onset HD. **(A)** Logistic regression of initial manifestation as recorded by the clinician, coded as binary variables (1: initial manifestation of that type, 0: initial manifestation of any other type) on age at onset. **(B)** Logistic regression of initial manifestation (defined as a binary variable, as above) on CAG length. Significant associations after Bonferroni correction for 12 models are shown in bold ($P < 4.17 \times 10^{-3}$) and nominally significant associations in italics ($P < 0.05$). The odds ratio (OR) indicates the effect on the outcome probability associated with an increase of ten years in age. Only individuals with a confirmed onset ≥20 years, CAG 36-59 and no schizophrenia co-morbidity (ICD-10 F20, F21 or F25) were included. N=6051 for both sets of models. CI: confidence interval.

	Motor (N=5363)		Cognitive (N=3141)		Apathy (N=2798)	
	OR (95% CI)	*P*	OR (95% CI)	*P*	OR (95% CI)	*P*
Exp CAG	0.94 (0.94 - 0.95)	**1.17×10^{-89}**	0.94 (0.93 - 0.95)	**7.38×10^{-51}**	0.93 (0.93 - 0.94)	**1.70×10^{-40}**
WT CAG	0.99 (0.98 - 1.01)	4.55×10^{-1}	0.99 (0.97 - 1.01)	2.76×10^{-1}	0.97 (0.95 - 0.99)	*6.98×10^{-3}*
Interaction	1.00 (1.00 - 1.00)	4.89×10^{-1}	1.00 (1.00 - 1.00)	3.48×10^{-1}	1.001 (1.00 - 1.00)	*6.51×10^{-3}*

	Depression (N=3439)		POB (N=1927)		Irritability (N=3165)	
	OR (95% CI)	*P*	OR (95% CI)	*P*	OR (95% CI)	*P*
Exp CAG	0.94 (0.93 - 0.95)	**1.49×10^{-19}**	0.95 (0.93 - 0.96)	**3.78×10^{-13}**	0.95 (0.94 - 0.96)	**7.37×10^{-17}**
WT CAG	0.99 (0.96 - 1.02)	3.69×10^{-1}	0.99 (0.96 - 1.02)	5.32×10^{-1}	1.02 (0.99 - 1.05)	1.63×10^{-1}
Interaction	1.000 (1.00 - 1.00)	3.26×10^{-1}	1.00 (1.00 - 1.00)	6.10×10^{-1}	1.00 (1.00 - 1.00)	1.67×10^{-1}

	VAB (N=1630)		Psychosis (N=597)	
	OR (95% CI)	*P*	OR (95% CI)	*P*
Exp CAG	0.94 (0.92 - 0.95)	**4.24×10^{-15}**	0.92 (0.90 - 0.95)	**5.28×10^{-8}**
WT CAG	0.98 (0.95 - 1.02)	4.12×10^{-1}	0.94 (0.88 - 1.00)	5.01×10^{-2}
Interaction	1.00 (1.00 - 1.00)	3.67×10^{-1}	1.00 (1.00 - 1.00)	*4.14×10^{-2}*

Table e-3. The CAG repeat length of the pathogenic *HTT* allele, but not the wild-type HTT allele, is associated with the presence of motor and psychiatric symptoms in HD. Logistic regression of binary symptom data (lifetime prevalence; 0 = no symptom, 1 = reported symptom) on expanded (36-93 CAGs) and wild-type (6-35 CAGs) repeat lengths, with an interaction term. Significant associations are in bold ($P < 2.08 \times 10^{-3}$, correcting for number of covariates and phenotypes), and nominal associations italicised ($P < 0.05$). The odds ratio (OR) indicates the effect on the outcome probability associated with an increase of one unit in the covariate. In addition to having a confirmed onset and pathogenic CAG length, to be included individuals must have a known sex and no co-morbid diagnosis of schizophrenia, schizotypy or schizoaffective disorder. CI: confidence interval; POB: perseverative/obsessive behaviour; VAB: violent or aggressive behaviour.

	Depressed mood (N=1721)		Suicidal ideation (N=1708)		Anxiety (N=1717)		Irritability (N=1727)	
	Effect (95% CI)	*P*	Effect (95% CI)	*P*	Effect (95% CI)	*P*	Effect (95% CI)	*P*
Motor	1.20 (±1.89)	$2.14X\ 10^{-1}$	0.60 (±0.87)	$1.79X\ 10^{-1}$	-0.66 (±1.83)	$4.80X\ 10^{-1}$	-0.05 (±1.94)	$9.61X\ 10^{-1}$
Cognitive	-0.18 (±0.37)	$3.28X\ 10^{-1}$	-0.09 (±0.17)	$3.18X\ 10^{-1}$	-0.02 (±0.36)	$8.94X\ 10^{-1}$	0.19 (±0.38)	$3.27X\ 10^{-1}$
Apathy	0.48 (±0.37)	*$1.15X\ 10^{-2}$*	0.12 (±0.17)	$1.69X\ 10^{-1}$	0.62 (±0.36)	*$8.44X\ 10^{-4}$*	0.39 (±0.38)	*$4.84X\ 10^{-2}$*
Depression	1.70 (±0.37)	**$2.19X\ 10^{-19}$**	0.39 (±0.17)	**$7.22x\ 10^{-6}$**	0.92 (±0.36)	**$4.54x\ 10^{-7}$**	-0.04 (±0.38)	$8.45x\ 10^{-1}$
POB	0.00 (±0.37)	$9.97X\ 10^{-1}$	0.09 (±0.17)	$2.95x\ 10^{-1}$	0.23 (±0.36)	$2.13x\ 10^{-1}$	0.37 (±0.38)	$5.33x\ 10^{-2}$
Irritability	0.68 (±0.39)	*$6.69X\ 10^{-4}$*	0.27 (±0.18)	*$3.44x\ 10^{-3}$*	0.62 (±0.38)	*$1.33x\ 10^{-3}$*	1.80 (±0.40)	**$4.39x\ 10^{-18}$**
VAB	0.07 (±0.41)	$7.28X\ 10^{-1}$	0.00 (±0.19)	$9.60x\ 10^{-1}$	0.22 (±0.40)	$2.85x\ 10^{-1}$	1.01 (±0.42)	**$2.31x\ 10^{-6}$**
Psychosis	-0.34 (±0.53)	$2.06X\ 10^{-1}$	0.10 (±0.25)	$4.17x\ 10^{-1}$	-0.12 (±0.52)	$6.58x\ 10^{-1}$	-0.25 (±0.54)	$3.60x\ 10^{-1}$
Age	-0.04 (±0.02)	**$1.98X\ 10^{-4}$**	-0.01 (±0.01)	*$4.23x\ 10^{-2}$*	-0.02 (±0.02)	*$2.73x\ 10^{-2}$*	-0.02 (±0.02)	*$2.00x\ 10^{-2}$*
CAG	-0.10 (±0.05)	**$2.39X\ 10^{-4}$**	-0.03 (±0.02)	*$1.82x\ 10^{-2}$*	-0.07 (±0.05)	*$5.68x\ 10^{-3}$*	-0.01 (±0.05)	$7.41x\ 10^{-1}$
Sex (F)	0.28 (±0.33)	$9.10X\ 10^{-2}$	-0.18 (±0.15)	*$2.18x\ 10^{-2}$*	0.14 (±0.32)	$3.94x\ 10^{-1}$	0.13 (±0.34)	$4.60x\ 10^{-1}$
Duration	-0.01 (±0.03)	$5.44X\ 10^{-1}$	0.00 (±0.01)	$9.63x\ 10^{-1}$	-0.01 (±0.03)	$4.93x\ 10^{-1}$	0.02 (±0.03)	$1.53x\ 10^{-1}$

	Angry or aggressive behaviour (N=1726)		Apathy (N=1719)		Perseverative thinking/ behaviours (N=1722)		Obsessive compulsive behaviours (N=1711)	
	Effect (95% CI)	*P*	Effect (95% CI)	*P*	Effect (95% CI)	*P*	Effect (95% CI)	*P*
Motor	0.42 (±1.57)	$6.05X\ 10^{-1}$	1.03 (±2.48)	$4.14X\ 10^{-1}$	1.40 (±2.16)	$2.05x\ 10^{-1}$	0.69 (±1.71)	$4.25x\ 10^{-1}$
Cognitive	0.35 (±0.31)	*$2.48X\ 10^{-2}$*	0.84 (±0.48)	*$6.25X\ 10^{-4}$*	0.60 (±0.42)	*$5.23x\ 10^{-3}$*	-0.02 (±0.33)	$9.10x\ 10^{-1}$
Apathy	0.22 (±0.31)	$1.63X\ 10^{-1}$	3.30 (±0.49)	**$5.15X\ 10^{-38}$**	0.43 (±0.43)	*$4.93x\ 10^{-2}$*	0.06 (±0.34)	$7.08x\ 10^{-1}$
Depression	0.00 (±0.31)	$9.88x\ 10^{-1}$	0.58 (±0.48)	*$1.89x\ 10^{-2}$*	0.54 (±0.42)	*$1.12x\ 10^{-2}$*	0.19 (±0.33)	$2.64x\ 10^{-1}$
POB	0.44 (±0.31)	*$5.29x\ 10^{-3}$*	0.61 (±0.48)	*$1.35x\ 10^{-2}$*	2.48 (±0.42)	**$5.56x\ 10^{-30}$**	1.27 (±0.33)	**$9.69x\ 10^{-14}$**
Irritability	0.52 (±0.33)	*$1.88x\ 10^{-3}$*	-0.01 (±0.51)	$9.80x\ 10^{-1}$	-0.06 (±0.45)	$7.82x\ 10^{-1}$	0.04 (±0.35)	$8.13x\ 10^{-1}$
VAB	1.51 (±0.34)	**$8.81x\ 10^{-18}$**	0.76 (±0.54)	*$5.58x\ 10^{-3}$*	0.25 (±0.47)	$2.99x\ 10^{-1}$	0.13 (±0.37)	$4.85x\ 10^{-1}$
Psychosis	0.21 (±0.44)	$3.63x\ 10^{-1}$	1.23 (±0.70)	*$5.50x\ 10^{-4}$*	0.94 (±0.61)	*$2.49x\ 10^{-3}$*	0.13 (±0.48)	$6.10x\ 10^{-1}$
Age	-0.01 (±0.02)	$2.21x\ 10^{-1}$	0.03 (±0.03)	$6.18x\ 10^{-2}$	0.01 (±0.02)	$2.95x\ 10^{-1}$	-0.04 (±0.02)	**$1.54x\ 10^{-4}$**
CAG	-0.01 (±0.04)	$5.57x\ 10^{-1}$	0.05 (±0.07)	$1.26x\ 10^{-1}$	0.07 (±0.06)	*$3.61x\ 10^{-2}$*	-0.07 (±0.05)	*$6.39x\ 10^{-3}$*
Sex (F)	0.01 (±0.27)	$9.47x\ 10^{-1}$	-0.47 (±0.43)	*$3.45x\ 10^{-2}$*	-0.12 (±0.38)	$5.34x\ 10^{-1}$	-0.26 (±0.30)	$8.45x\ 10^{-2}$
Duration	0.02 (±0.03)	$1.75x\ 10^{-1}$	0.05 (±0.04)	*$1.84x\ 10^{-2}$*	0.04 (±0.04)	*$4.62x\ 10^{-2}$*	0.04 (±0.03)	*$8.24x\ 10^{-3}$*

	Delusions/paranoid thinking (N=1708)		Hallucinations (N=1710)		Disorientated behaviour (N=1701)	
	Effect (95% CI)	*P*	Effect (95% CI)	*P*	Effect (95% CI)	*P*
Motor	0.20 (±0.95)	6.87×10^{-1}	0.02 (±0.54)	9.31×10^{-1}	0.67 (±1.48)	3.73×10^{-1}
Cognitive	-0.03 (±0.18)	7.16×10^{-1}	0.01 (±0.10)	8.22×10^{-1}	0.80 (±0.29)	**6.53×10^{-8}**
Apathy	0.00 (±0.18)	9.85×10^{-1}	0.09 (±0.11)	9.44×10^{-2}	0.20 (±0.29)	1.93×10^{-1}
Depression	0.16 (±0.18)	7.10×10^{-2}	0.05 (±0.10)	3.97×10^{-1}	0.08 (±0.29)	5.73×10^{-1}
POB	0.03 (±0.18)	7.35×10^{-1}	-0.04 (±0.10)	4.58×10^{-1}	0.45 (±0.29)	*2.13×10^{-3}*
Irritability	0.11 (±0.19)	2.42×10^{-1}	-0.10 (±0.11)	6.80×10^{-2}	-0.21 (±0.31)	1.79×10^{-1}
VAB	0.00 (±0.20)	9.94×10^{-1}	-0.01 (±0.12)	9.16×10^{-1}	0.59 (±0.32)	**3.44×10^{-4}**
Psychosis	1.19 (±0.26)	**5.56×10^{-19}**	0.81 (±0.15)	**4.67×10^{-25}**	0.68 (±0.42)	*1.60×10^{-3}*
Age	-0.01 (±0.01)	3.08×10^{-1}	0.00 (±0.01)	5.61×10^{-1}	0.03 (±0.02)	*8.23×10^{-4}*
CAG	-0.01 (±0.03)	2.81×10^{-1}	0.00 (±0.02)	6.33×10^{-1}	0.03 (±0.04)	1.28×10^{-1}
Sex (F)	0.07 (±0.16)	4.19×10^{-1}	-0.08 (±0.09)	9.84×10^{-2}	-0.07 (±0.26)	5.75×10^{-1}
Duration	0.02 (±0.02)	*2.81×10^{-2}*	0.00 (±0.01)	2.92×10^{-1}	0.05 (±0.03)	**2.92×10^{-4}**

Table e-4. Scores for neuropsychiatric symptoms from the short-form Problem Behaviors Assessment questionnaire (PBA-s) correlate with specific responses from the HD clinical characteristics questionnaire (HD-CCQ). Generalised linear models regressed the product of the frequency and severity scores from PBA-s questions against binary lifetime prevalence data on 8 symptoms from the HD Clinical Characteristics Questionnaire (italics, column 1) and other covariates. For binary covariates (CCQ symptoms and sex) “effect” is the increase/decrease in the clinical score associated with presence of that covariate. For quantitative covariates (age, CAG, duration), “effect” is the change in clinical score associated with an increase of one unit in the covariate. In addition to having a confirmed onset and pathogenic CAG length (36-93), individuals must have no co-morbid diagnosis of schizophrenia, schizotypy or schizoaffective disorder. Significant associations after Bonferroni correction for 11 phenotypes and 12 covariates are shown in bold ($P < 3.79 \times 10^{-4}$) and nominally significant *P* values are italicised ($P < 0.05$). CI: confidence interval; POB: perseverative/ obsessive behaviour; VAB: violent or aggressive behaviour; Sex (F): female.



Figure e-1. Histogram of pure CAG repeat lengths against frequency for the Registry population analysed in this study. Shown are *HTT* CAG length frequencies for the largest pathogenic CAG (36-93) in individuals with clinical onset of HD (N=6316).



Figure e-2. The onsets of cognitive and psychiatric symptoms relative to motor onset in HD. The age at onset of motor symptoms was subtracted from the age at onset of each cognitive/psychiatric symptom when present. Timings of up to +/- 40 years relative to motor onset shown. Only individuals with a rater-confirmed age at onset and CAG length (36-93) were included. Data from HD-CCQ. (**A**) Perseverative/obsessive behaviour (POB) N=1973, skew = -1.54; (**B**) Violent or aggressive behaviour (VAB) N=1663, skew = -1.30; (**C**) Psychosis N=619, skew = -0.46. Only individuals with a known age at onset and CAG length (36-93) were included.